MSACL 2022 : Conference Program Monterey, CA • April 5-8, 2022

Abstract Clinical Use Status Key

= Discovery stage. (19.79%, 2022) = Translation stage. (37.97%, 2022) = Clinically available. (42.25%, 2022)

MON Early Check-In TUE Short Courses Workshops Plenaries Posters WED Plenaries Scientific Sessions Posters THU Plenaries Scientific Sessions Posters FRI Plenaries Short Courses Workshops ALL View All Posters View Abstracts by Topic Assays Leveraging MSCases in Clinical MSData AnalyticsEmerging TechnologiesGlycomicsIdentifying High Value TestsImagingLipidomicsLogistics for Bringing Basic Science to the ClinicMetabolomicsMicrobiologyMulti-omicsPractical TrainingPre-AnalyticsProteomicsTox / TDM / EndocrineTroubleshootingVarious OTHER View Abstracts by Presenter Abddelgader, RashaAli, MahesheemaAndrews, BrookeArowolo, FolagbayiAslan, JosephBadea, AdinaBajaj, AmolBalcı, MehmetBasu, Sankha (Bobby)Bevins, NicholasBishop, LaurenBorchers, ChristophBorges, ChadChambers, TinaChandu, KarthikChaparala, AnushaChapman, JessicaChen, XiaohongChoucair, IbrahimChouinard, ChristopherClarke, JosephCohen, PeterCollier, TimothyCrawford, MatthewCua, AgnesDemianova, ZuzanaDing, HaiqingDoykov, IvanDrabovich, AndreiDubland, JoshuaEdelman, JonathanFariha, RamisaFeizbakhsh Bazargani, SinaFitch, BrianaFrank, ElizabethFu, XiaoweiFyffe-Freil, RiaGagnon, HugoGanepola, DevanjithGarza, KyanaGeere, MimaGethings, LeeGibson, RichardGill, ChrisGirton, MarkGlobisch, DanielGomez, GermanGrant, RussellGuo, JingshuGuturu, HarendraHarrsch, PeterHauck, ZaneHe, XiangHeywood, WendyHitchcock, JenniferHoedt, EsthelleHolmquist, BrettHolt, CrystalHoofnagle, AndyHornburg, DanielHu, TonyHuq, ShahanaJensen, TrinitiKafle, AmolKaufmann, MartinKeevil, BrianKemp, JenniferKilpatrick, MadisonKing, JenniferKirkpatrick, LindseyKoch, ChristopherKoomen, JohnKoussiouris, JohnKratz, DanielKumar, RashmiKushnir, MarkKutnick, AdamKuzdzal, ScottLadwig, PaulaLaPalme, JamesLebert, DorotheeLee, AndrewLi, YaxinLiao, Hsuan-Chieh (Joyce)Lima, HeatherLin, YuanLiu, DantingLongman, KatieLuo, Ruben Y.Lynch, KaraMackowsky, DanielleMadunić, KatarinaMalaeb, HindMarshall, LucasMaus, AnthonyMaxwell, ColleenMaynard, RobertMehta, KhyatiMellinger, AllysonMerrigan, StephenMiao, JessieMichno, WojciechMiller, IraMoehnke, KaylaMoradian, AnnieMotorykin, IevgenNedelkov, DobrinNegri, PierreNewcombe, DavidNguyen, NguyenNicolas, MoutonOetjen, KarlOlayinka, LilyOmosule, CatherinePablo, AbedPark, Jong-MinPhinney, KarenPlubell, DeannaPongracz, TamasPonzetto, FedericoPrentice, BooneRakic, BojanaRasmussen, NatalieRay, JulieRodriguez-Temporal, DavidRoper, StephenRoss, M. JamesRoss, JohnRuhaak, ReneeSchofield, RyanSeegmiller, JesseSenior, AdamSetchell, KennethShao, LeiSimmermaker, CateSimon, FabianSingh, RavinderSmith, KathrynSong, YvonneSuhandynata, RaymondSwanson, CarterSzczesniewski, AndrzejTang, XiaoyingThan, Nandor GaborThorsteinsdottir, MargretTsiara, IoannaVachali, Preejithvan Natta, KristineVanderboom, PatrickVerhaert, PeterWang, EvelynWeatherill, JamesWentworth, CarolineWillrich, MariaWong, MauriceWoolfork, AshleyYannell, KarenYates, JohnZhang, XuZhao, Xueheng

Monday

Monday 1600 1900

Early Badge Pickup @ De Anza Foyer 1888

Monday 1600 2000

Welcome Hospitality Reception @ Jacks Inside of Jacks Club Room Drinks and very light snacks, not intended as a dinner substitute. 1889

Tuesday

Tuesday 630

Registration Desk Opens @ De Anza Foyer 1906

Tuesday 800 1600

Vendor Booth Set-Up @ Exhibit Hall - Serra 1962

Tuesday 800 1200

Workshop: A Clinical Proteomics Primer @ De Anza 1 Andy Hoofnagle, MD, PhD University of Washington Dr. Hoofnagle's laboratory focuses on the precise quantification of recognized protein biomarkers in human plasma using LC-MRM/MS. In addition, they have worked to develop novel assays for the quantification of small molecules in clinical and research settings. His laboratory also studies the role that the systemic inflammation plays in the pathophysiology of obesity, diabetes, and cardiovascular disease. Financial Disclosures (past 24 months as of Feb 13, 2024) Grants/Research Expenses: Waters The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Christopher Shuford, PhD Labcorp Chris Shuford, Ph.D., is Associate Vice President and Technical Director for research and development at Laboratory Corporation of America in Burlington, North Carolina. Chris received his B.S. in Chemistry & Physics at Longwood University and obtained his Ph.D. in Bioanalytical Chemistry from North Carolina State University under the tutelage of Professor David Muddiman, where his research focused on applications of nano-flow chromatography for multiplexed peptide quantification using protein cleavage coupled with isotope dilution mass spectrometry (PC-IDMS). In 2012, Chris joined LabCorp’s research and development team where his efforts have focused on development of high-flow chromatographic methods (>1 mL/min) for multiplexed and single protein assays for clinical diagnostics. Financial Disclosures (past 24 months as of Feb 12, 2024) Stocks/Bonds: LabCorp Salary: LabCorp The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Objective To provide an interactive forum in which attendees will be introduced to critical aspects of clinical protein measurements. Summary The motivation for using mass spectrometry to quantify proteins in clinical research and in clinical care will be discussed as part of this interactive workshop. Technical topics uniquely affecting quantitative protein and peptides measurements by mass spectrometry will be a point of emphasis. Case studies from assay inception through validation will be presented and participants will work interactively to critique various aspects of clinical proteomic measurements. Syllabus - Protein vs Peptide Measurands - Workflows - Sample Preparation (Digestion & Enrichment) - Internal standards - Calibration - Validation - Quality control 1853

Tuesday 800 1200

Workshop: Why We Fail at Biomarkers @ De Anza 3 Tim Garrett, PhD University of Florida College of Medicine Dr. Garrett has over 20 years of experience in the field of mass spectrometry spanning both instrument and application development. He received his PhD from the University of Florida, under Dr. Richard A. Yost, working on the first imaging mass spectrometry-based ion trap instrument. He has also developed MALDI-based approaches to analyze proteins in bacteria and small molecules in tissue specimens. His current interests include the translation of LC-HRMS, MALDI, DESI and LMJSSP in metabolomics to clinical diagnostics. He is an Associate Professor in the Department of Pathology at the University of Florida, and an Associate Director for the Southeast Center for Integrated Metabolomics (SECIM). Financial Disclosures (past 24 months as of Feb 13, 2024) Grants/Research Expenses: Capitainer, Agilent Technologies, ThermoFisher The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Objective This workshop is designed to teach attendees reasons why most biomarkers do not translate to clinical diagnostics as a way to improve the process for future research Summary Biomarker discovery is one of the major areas of clinical research especially in metabolomics yet less than 1% of published biomarkers translate to clinical diagnostics. Biomarker discovery generally starts in phase 1 with a few samples to identify a biomolecule that differentiates the disease or disorder under investigation from control samples. Once a biomolecule is selected a targeted quantitative method would be developed in phase 2 to use on a larger number of samples to validate the results from phase 1. There are several common reasons for biomarker failure such as using samples that are not representative of the clinical population, not including diversity in the initial discovery phase, improper use of statistical approaches, not having a sufficient number of samples and improper quality control for analysis. With the growth of metabolomic methods recently, a discussion on approaches to help improve phase 1 of biomarker discovery is important to have confidence that the selected markers are indeed unique. Syllabus - Metabolomics in clinical research - Quality control for better method assessment - Experimental design - Statistical analyses with validation - Real-world samples 1897

Tuesday 800 1200

Short Course: Data Science 101 : Breaking up with Excel: An Introduction to the R Statistical Programming Language @ Bonsai Daniel Holmes, MD, FRCPC St. Paul’s Hospital Daniel Holmes did his undergraduate training in Chemistry and Physics at the University of Toronto before deciding to pursue medicine as a career. He attended medical school at the University of British Columbia where pathology became his area of major interest. The strong influence of his academic mentors led him to enter the Medical Biochemistry residency training program at UBC. This allowed him to use his background knowledge of chemistry in application to medicine. Areas of clinical interest are diagnostic lipidology/endocrinology and research interests are in the utilization of mathematics and computer diagnostics to laboratory medicine. Financial Disclosures (past 24 months as of Nov 15, 2024) Expenses/Honoraria: St. Paul's Hospital Consultancy: St. Paul's Hospital Grants/Research Expenses: St. Paul's Hospital Stocks/Bonds: St. Paul's Hospital Board/Committee: St. Paul's Hospital Salary: St. Paul's Hospital Company Ownership: St. Paul's Hospital The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Dustin Bunch, PhD, DABCC Nationwide Children's Hospital Dustin R. Bunch, is an Asst. Director of Clinical Chemistry & Co-Director Laboratory Informatics at Nationwide Children's Hospital. His research focuses small molecule analysis by mass spectrometry in a clinical setting and clinical informatics. Financial Disclosures (past 24 months as of Feb 13, 2024) : none ** Part In-Person (optional, also available pre-recorded) and Part Online ** This is the first segment (4 hr) of a three segment (16hr total), part in-person (optional) and part online, short course. Segment 1 will be available both IN-PERSON on April 5 at the MSACL 2022 conference in Monterey, CA and ONLINE (pre-recorded) if you can't make it in person. Registration for Segment 1 is free (although to attend on-site you must be registered for MSACL 2022). Segments 2 and 3 will take place ONLINE on April 29-30, 2022. While the first SEGMENT is FREE, SEGEMENTS 2 and 3 that occur only ONLINE are fee-based. You can REGISTER HERE. ---------- Does Excel lag on you when you open a file bigger than 1000 rows? Has it ever changed your data to a date against your will? Are you ready to jump right past Tableau and into the world of Data Science using a real programming language? Well, your wait is over because at MSACL we again will be offering a course for complete programming newbies that will help you get going analyzing real data related to LC-MS/MS assay development, validation, implementation and publication. The only background expected is the ability to use a spreadsheet program. The skills that you will acquire will allow you to take advantage of the many tools already available in the R language and thereafter, when you see that your spreadsheet program does not have the capabilities to do what you need, you will no longer have to burst into tears. The course will be run over three days (one in person to start and two online later) and time will be evenly split between didactic sessions and hands on problem solving with real data sets. Drs Holmes and Bunch will adopt a “no student left behind policy”. Students will be given ample time to solve mini problems taken from real life laboratory work and focused on common laboratory tasks. All attendees will need to bring a laptop with the R language installed R Studio interface installed. Students may use Windows, Mac OSX or Linux environments. Both R and R studio are free and open-source. No cash required. Students should be prepared for learning what computer programming is really like. This may involve some personal frustration but it will be worth it. Obtaining the Software !!! DOWNLOAD PROGRAM PACKAGES PRIOR TO ARRIVAL ONSITE !!! THERE WILL NOT BE OPEN INTERNET WIFI IN THE CONFERENCE CENTER. !!! POWER : Make sure your computer is charged to hold power for 4 hrs, as power outlets may not be available. Instructions for installing the R language are here: http://cran.r-project.org/ Instructions for installing R Studio are here: http://www.rstudio.com/ Course Description The course will cover: The major types of R variables: vectors (numerical, character, logical), matrices, data frames and lists. The important classes: numeric, character, list and changing between them Importing data from Excel Dealing with non-numeric instrument data Manipulating and cleansing your data Exporting data to Excel-like format. Basics of tidyverse: dplyr, filter, mutate, join Regressions: ordinary least squares,Passing Bablok, Deming, weighted regressions. Non-linear regressions Looping: Doing things repeatedly group_by and summarize Writing your own functions Making highly customized figures with base plot or ggplot Putting it all together projects: Preparing method comparison regression and Bland Altman plots Preparing mass spectrometry data for upload to LIS. 1854

Tuesday 800 950

Short Course: LC-MSMS 101 : Hands-On Training Session (GROUP 1) @ Colton Judy Stone, MT (ASCP), PhD, DABCC Clinical Chemist (retired) Judy Stone, MT (ASCP), PhD, DABCC has worked with LC-MS in diagnostic laboratories since 1999. Her clinical practice involved small molecule method development, instrument to instrument and instrument to LIS interfacing, LC-MS automation, monitoring quality of LC-MS methods in production and staff training for clinical LC-MSMS. She served as faculty chair for the 2009 AACC online certificate program “Using Mass Spectrometry in the Clinical Laboratory”, as a scientific committee member for the MSACL Practical Training track, and was editor-in-chief for the AACC Clinical Laboratory News quarterly feature series on Clinical LC-MS. She enjoys documenting and presenting esoteric as well as absurdly common LC-MS problems in creative ways in order to help trainees learn troubleshooting (and avoid repeating her mistakes). Financial Disclosures (past 24 months as of Feb 15, 2024) : none Jacqueline Hubbard, PhD, DABCC Beth Israel Deaconess Medical Center, Harvard Medical School Jacqueline Hubbard received her BS degree in Biochemistry from the University of Vermont. She then earned her MS and PhD in Biochemistry and Molecular Biology from the University of California, Riverside (UCR). Following a one year postdoc at UCR, Dr. Hubbard completed a Fellowship in Clinical Chemistry at the University of California, San Diego Health. She is board certified in Clinical Chemistry by the American Board of Clinical Chemistry. In 2019, she took a position as an Assistant Professor in the Department of Pathology and Laboratory Medicine at the Geisel School of Medicine at Dartmouth and as the Assistant Director of Clinical Chemistry at Dartmouth-Hitchcock Medical Center. There, she focused on developing and validating drugs of abuse assays and SARS-CoV-2 serology testing. After serving as a Lab Director for a small reference laboratory, she joined Beth Israel Deaconess Medical Center as the Co-Director of Clinical Chemistry and Director of Toxicology in 2024. She is also an Assistant Professor of Pathology for Harvard Medical School. Her research focus still includes mass spectrometry method development and toxicology test interpretation. Financial Disclosures (past 24 months as of Nov 11, 2024) Salary: Three Rivers Diagnostics The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Adina Badea, PhD, DABCC Lifespan/Rhode Island Hospital & the Warren Alpert Medical School of Brown University Dr. Adina Badea, PhD, DABCC, earned her BA in Chemistry from Wellesley College, and her PhD in Chemistry from the University of Illinois at Urbana-Champaign. She completed her clinical chemistry and toxicology fellowship at UCSF, where she worked under the supervision of Dr. Alan Wu and Dr. Kara Lynch on developing methods and finding new solutions to current challenges in clinical toxicology testing. Currently, she is Director of Toxicology at Rhode Island Hospital and Assistant Professor of Pathology and Laboratory Medicine at The Warren Alpert Medical School of Brown University, where she focuses on expanding the capabilities of the clinical toxicology lab using high resolution mass spectrometry. Her research interests include bringing state-of-the-art testing to the service of emergency medicine patients and to address public health crises with real-time comprehensive toxicology testing via collaborations with the local Poison Control Center and Department of Health. Financial Disclosures (past 24 months as of Dec 21, 2023) : none Robert Fitzgerald, PhD, DABCC University of California San Diego Robert L. Fitzgerald, PhD, DABCC Dr. Fitzgerald received his BS degree in Chemistry at Loyola College of Maryland, and his PhD in Pharmacology/Toxicology at the Medical College of Virginia/Virginia Commonwealth University. After two and a half years as a forensic toxicologist for the State of Virginia, he took a position as the Director of the Mass Spectrometry Laboratory at the San Diego VA Hospital. Currently, Dr. Fitzgerald is a Professor in the Department of Pathology at the University of California, San Diego where he is the director of the toxicology laboratory and associate director of the clinical chemistry laboratory. He is board certified in toxicology and clinical chemistry by the American Board of Clinical Chemistry. He is the director of the clinical chemistry fellowship at UCSD. Financial Disclosures (past 24 months as of Apr 18, 2023) : none Sponsored in part by: ** Supplemental Hands-On Segment In-Person : Main Course is Online ** This is the supplemental bonus segment (2 hr) of a 16 hour online short course taking place on March 11-14, 2022. Attendance at this in-person segment is free, but REQUIRES pre-registration (separate from conference registration, coming soon) with priority given to online course registrants. There will be two instances of this segment (Group 1 and Group 2, both the same), with each to be capped at 20 participants. You can register for the online course (fee-based) here. ---------- Is this workshop for you? This two hour workshop is a supplement to the MSACL Online Short Course – “Getting Started with Quantitative LC-MS/MS in the Diagnostic Laboratory (LC-MS 101)”. The short course will be offered online, March 11-14, 2022 (register here). The hands-on workshop content is designed for attendees from the online short course, but the short course is not a prerequisite. Anyone starting out with quantitative LC-MS troubleshooting may find it useful. Format and Content The first 50 min session will include brief instructor demonstrations and then ample hands-on time for attendees to practice troubleshooting tasks, such as - cutting (and recutting) PEEK tubing correctly - connecting (and reconnecting) PEEK fittings to LC columns, other components - changing LC pump check valves - changing LC injection valve rotor seals - reviewing chromatography problems caused by leaks, tubing/fitting mistakes and damage, excess LC dead volume, and aged LC components The second 50 min session is a discussion of real world instrument troubleshooting cases from the instructors’ laboratories. Aside from the examples presented, the goal is to develop a standardized approach to troubleshooting complex LC-MS systems, including - Know your LC flow path and LC components, how to avoid damaging the MS/MS - How to look for leaks and sources of overpressure - Using chromatogram overlays, pressure traces, maintenance chart review, system suitability testing and MS/MS infusion to locate the problem within the instrument 1850

Tuesday 900 1200

Workshop : How to Convince Admin THEY Want to Buy You a Mass Spectrometer @ De Anza 2 Joshua Hayden, PhD, DABCC, FACB Norton Healthcare Joshua is currently the Chief of Chemistry at NortonHealthcare. He earned his PhD in chemistry from Carnegie Mellon University. He conducted postdoctoral research at Massachusetts Institute of Technology before completing a two-year clinical chemistry fellowship at University of Washington and 4 years as Assistant Professor at Weill Medical College. Joshua has special expertise developing and overseeing mass spectrometry assays in the clinical laboratory. Financial Disclosures (past 24 months as of Feb 13, 2024) Board/Committee: BioPorto The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Juan David Garcia, MBA MT University Of Texas Medical Branch JUAN D. GARCIA, MBA MLS Mr. Garcia has more than 20 years of extensive experience in healthcare and medical laboratory industry having worked and managed a wide range of settings including large medical centers with multiple in-house laboratories, multi-hospital systems, academic healthcare institutions, and hospital-based outreach facilities. He specializes in business and strategic planning, operations management, operations analysis & improvement, quality assessment and improvement, lean/six sigma process improvement, information system/LIS integration, system evaluation, selection and implementation, vendor consulting and subrogation, outreach development as well as team building and employee engagement. Mr. Garcia holds a strong technical knowledge in multiple lab disciplines through the earlier years of working in the laboratory field. The combination of superior technical and business qualifications allowed him to understand healthcare and laboratory business from multiple perspectives and have the ability to analyze an organization’s critical business requirements, identify deficiencies and opportunities and provide innovative and cost-effective solutions for enhancing operations with financial success. Mr. Garcia currently works as the Administrative Director for the Laboratory Services at University of Texas Medical Branch in Galveston, TX. Prior to this, he directed the Central Laboratory Services at New York Presbyterian Hospital Weill Cornell Medical Center in New York and managed the Laboratory Services at the University of Miami in Miami Fl. He also is the founder and former Director of HCLA (HealthCare & Laboratory Advisors) consulting firm. Mr. Garcia received his MBA in Management and HealthCare Management from the Business School at University of Miami and a Bachelor of Science in Medical Laboratory Science from University of Valle in Cali Colombia. He is also Lean/Six Sig Sigma Green Belt certified and an active member of several management and professional organizations. Financial Disclosures (past 24 months) : Not reported Objectives The objective of this workshop is to give attendees the knowledge necessary to put together a convincing business case for purchasing a mass spectrometer. This knowledge will be imparted by presenting and discussing successful and unsuccessful examples of such business cases. Throughout the course, essential business terminology will be presented and explained. Summary Many laboratorians can discuss the benefits of implementing mass spectrometry into the clinical laboratory. From improved confidence in results to minimization of interferences, there are substantial and well-discussed benefits to mass spectrometry. Unfortunately, mass spectrometers cost money and the individuals empowered to write checks rarely relate to such technical justifications. This workshop is designed to help clinical laboratorians understand what factors matter to financial decision makers. The presenters include a clinical laboratorian with experience successfully acquiring mass spectrometers and an experienced administrator with significant laboratory and financial expertise. The presenters will walk attendees through the process of preparing a business case. Attendees will be presented with numerous examples of business cases that need improved and the attendees will be given the chance to discuss what is wrong and what needs to be done to fix them. Attendees will also be given a chance to submit their own personal business cases ahead of time if desired. These can be discussed in private after the workshop or (with attendee permission) can be discussed in part as part of the workshop. The goal is to prepare attendees to put together and present a business case that supports the acquisition of a mass spectrometer in terms that matter to financial decision makers. Syllabus/Topics How to assemble the worst business case ever (and guarantee failure) Attendees will begin the session with an introduction to the worst possible business case one can present. The numerous flaws will be pointed out and addressed in an effort to highlight the many ways business cases can go wrong. From LCMS and qTOF to ROI and DEPR (speaking the language of finance) After attendees have a chance to see what not to do, it will be time to discuss what administrators/finance officers are looking for in a business plan. The goal is that attendees walk away with an understanding of the important terms and metrics their business cases will be evaluated by. In addition, an overview of hospital accounting and do's and don't's of capital equipment purchasing will be given. Estimating costs The cost of a mass spectrometer is far more than the instrument itself. This section will help attendees begin to consider everything they need to account for when proposing how much mass spectrometry will cost- labor, supplies, service contract, etc. Estimating reimbursement This section will cover how to estimate revenue- whether it is insourcing from a reference lab or setting up a new service line. The importance of payer mix and inpatient vs outpatient will be addressed What's wrong with my business case? Ending where the course started, the final section will cover examples of business cases. These cases will be used to illustrate cases that are very strong and those with weaknesses that can be improved. If submitted by attendees ahead of time, these example cases will be anonymized versions of those submissions. 1896

Tuesday 1000 1150

Short Course: LC-MSMS 101: Hands-On Training Session (GROUP 2) @ Colton Judy Stone, MT (ASCP), PhD, DABCC Clinical Chemist (retired) Judy Stone, MT (ASCP), PhD, DABCC has worked with LC-MS in diagnostic laboratories since 1999. Her clinical practice involved small molecule method development, instrument to instrument and instrument to LIS interfacing, LC-MS automation, monitoring quality of LC-MS methods in production and staff training for clinical LC-MSMS. She served as faculty chair for the 2009 AACC online certificate program “Using Mass Spectrometry in the Clinical Laboratory”, as a scientific committee member for the MSACL Practical Training track, and was editor-in-chief for the AACC Clinical Laboratory News quarterly feature series on Clinical LC-MS. She enjoys documenting and presenting esoteric as well as absurdly common LC-MS problems in creative ways in order to help trainees learn troubleshooting (and avoid repeating her mistakes). Financial Disclosures (past 24 months as of Feb 15, 2024) : none Jacqueline Hubbard, PhD, DABCC Beth Israel Deaconess Medical Center, Harvard Medical School Jacqueline Hubbard received her BS degree in Biochemistry from the University of Vermont. She then earned her MS and PhD in Biochemistry and Molecular Biology from the University of California, Riverside (UCR). Following a one year postdoc at UCR, Dr. Hubbard completed a Fellowship in Clinical Chemistry at the University of California, San Diego Health. She is board certified in Clinical Chemistry by the American Board of Clinical Chemistry. In 2019, she took a position as an Assistant Professor in the Department of Pathology and Laboratory Medicine at the Geisel School of Medicine at Dartmouth and as the Assistant Director of Clinical Chemistry at Dartmouth-Hitchcock Medical Center. There, she focused on developing and validating drugs of abuse assays and SARS-CoV-2 serology testing. After serving as a Lab Director for a small reference laboratory, she joined Beth Israel Deaconess Medical Center as the Co-Director of Clinical Chemistry and Director of Toxicology in 2024. She is also an Assistant Professor of Pathology for Harvard Medical School. Her research focus still includes mass spectrometry method development and toxicology test interpretation. Financial Disclosures (past 24 months as of Nov 11, 2024) Salary: Three Rivers Diagnostics The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Adina Badea, PhD, DABCC Lifespan/Rhode Island Hospital & the Warren Alpert Medical School of Brown University Dr. Adina Badea, PhD, DABCC, earned her BA in Chemistry from Wellesley College, and her PhD in Chemistry from the University of Illinois at Urbana-Champaign. She completed her clinical chemistry and toxicology fellowship at UCSF, where she worked under the supervision of Dr. Alan Wu and Dr. Kara Lynch on developing methods and finding new solutions to current challenges in clinical toxicology testing. Currently, she is Director of Toxicology at Rhode Island Hospital and Assistant Professor of Pathology and Laboratory Medicine at The Warren Alpert Medical School of Brown University, where she focuses on expanding the capabilities of the clinical toxicology lab using high resolution mass spectrometry. Her research interests include bringing state-of-the-art testing to the service of emergency medicine patients and to address public health crises with real-time comprehensive toxicology testing via collaborations with the local Poison Control Center and Department of Health. Financial Disclosures (past 24 months as of Dec 21, 2023) : none Robert Fitzgerald, PhD, DABCC University of California San Diego Robert L. Fitzgerald, PhD, DABCC Dr. Fitzgerald received his BS degree in Chemistry at Loyola College of Maryland, and his PhD in Pharmacology/Toxicology at the Medical College of Virginia/Virginia Commonwealth University. After two and a half years as a forensic toxicologist for the State of Virginia, he took a position as the Director of the Mass Spectrometry Laboratory at the San Diego VA Hospital. Currently, Dr. Fitzgerald is a Professor in the Department of Pathology at the University of California, San Diego where he is the director of the toxicology laboratory and associate director of the clinical chemistry laboratory. He is board certified in toxicology and clinical chemistry by the American Board of Clinical Chemistry. He is the director of the clinical chemistry fellowship at UCSD. Financial Disclosures (past 24 months as of Apr 18, 2023) : none Sponsored in part by: ** Supplemental Hands-On Segment In-Person : Main Course is Online ** This is the supplemental bonus segment (2 hr) of a 16 hour online short course taking place on March 11-14, 2022. Attendance at this in-person segment is free, but REQUIRES pre-registration (separate from conference registration, coming soon) with priority given to online course registrants. There will be two instances of this segment (Group 1 and Group 2, both the same), with each to be capped at 20 participants. You can register for the online course (fee-based) here. ---------- Is this workshop for you? This two hour workshop is a supplement to the MSACL Online Short Course – “Getting Started with Quantitative LC-MS/MS in the Diagnostic Laboratory (LC-MS 101)”. The short course will be offered online, March 11-14, 2022 (register here). The hands-on workshop content is designed for attendees from the online short course, but the short course is not a prerequisite. Anyone starting out with quantitative LC-MS troubleshooting may find it useful. Format and Content The first 50 min session will include brief instructor demonstrations and then ample hands-on time for attendees to practice troubleshooting tasks, such as - cutting (and recutting) PEEK tubing correctly - connecting (and reconnecting) PEEK fittings to LC columns, other components - changing LC pump check valves - changing LC injection valve rotor seals - reviewing chromatography problems caused by leaks, tubing/fitting mistakes and damage, excess LC dead volume, and aged LC components The second 50 min session is a discussion of real world instrument troubleshooting cases from the instructors’ laboratories. Aside from the examples presented, the goal is to develop a standardized approach to troubleshooting complex LC-MS systems, including - Know your LC flow path and LC components, how to avoid damaging the MS/MS - How to look for leaks and sources of overpressure - Using chromatogram overlays, pressure traces, maintenance chart review, system suitability testing and MS/MS infusion to locate the problem within the instrument 1932

Tuesday 1000 1145

Workshop: Design of Experiments for Development and Optimization of LC-MS Clinical Diagnostic Assay @ Steinbeck 1 Margret Thorsteinsdottir, PhD University of Iceland Professor in Pharmaceutical Analytical Chemistry at the Faculty of Pharmaceutical Sciences, University of Iceland and R&D Director of ArcticMass LTd, Reykjavik, Iceland. Dr. Thorsteinsdóttir received her PhD from Uppsala University, Sweden in 1998. From 2000 to 2009 she was the managing director of Bioanalytical Laboratories at deCODE Genetics, Reykjavik, Iceland. She has extensive experience in development of analytical methods for metabolite profiling and quantification of clinical biomarkers in various biofluids utilizing chemometrics with the goal of improved clinical management of patients towards personalized patient care. Her current research interest includes studies of lipid metabolism in cancer cells and profiling plasma derived biomarkers for early detection of BRCA-related breast cancer. She is responsible for implementation of clinical mass spectrometry for support of diagnostics and therapeutic drug monitoring in collaboration with ArcticMass and the Landspitali University Hospital, Reykjavik, Iceland with major focus on quantitative targeted proteomics for clinical diagnosis. She is a principal investigator of the Icelandic Research Rannis projects, profiling metabolites for breast cancer diagnosis and search for novel biomarkers for early breast cancer diagnosis by metabolomics. Dr. Thorsteinsdóttir is a principal investigator for the Marine Biotechnology ERA-net project CYNOBESITY and the Horizon 2020 project MossTech, with the main task to isolate, identify and structurally characterize bioactive compounds from cyanobacteria, Icelandic mosses and liverworts. She is one of the founders of Females in Mass Spectrometry (FeMS), she is a vice-leader of the working group clinical significance and applications of (epi)lipidomics in the pan-European network, EpiLipidNET and vice-chair of the Nordic Metabolomics Society. Financial Disclosures (past 24 months as of Jul 11, 2024) : none Finnur Eiriksson, PhD ArticMass Financial Disclosures (past 24 months as of Feb 13, 2024) : none Objectives The objective of the workshop is to provide an introduction into design of experiments (DoE) for clinical application with special focus on optimization of MS-based bioanalytical assays. The workshop is focused on practical implementation of DoE and will demonstrate how method development of UPLC-MS/MS clinical diagnostic methods can become much more efficient by utilizing DoE. Summary The chemometric approach, design of experiments (DoE) is an efficient tool for development and optimization of UPLC-MS/MS for quantification of biomarkers in complex biological matrices. The UPLC-MS/MS platform is composed of several processes which involves many experimental factors that need to be simultaneously optimized to obtain maximum sensitivity with adequate resolution at minimum retention time. DoE offers a practical approach for performing experiments in accordance to predefined plan, modelling by empirical functions, and graphical visualization. Basic concept of DoE will be presented with emphasis on practical implementation of DoE which include the three main stages, screening, optimization, and robustness testing. Example from optimization of a UPLC-MS/MS method for clinical diagnostic purposes and therapeutic drug monitoring will be used to show the cost-effective benefit of DoE, where it allows the effect of variables to be assessed with only a fraction of the experiments that would be required by changing one-separate-factor-at-time (COST) approach. A fractional factorial design was used for experimental screening to reveal the most influential experimental factors. When multi-levels qualitative factors were included in the screening experiments D-optimal design was applied. Significant factors were studied via central composite design and related to sensitivity, resolution and retention time utilizing partial least square (PLS)-regression. A specific and reliable UPLC-MS/MS assay for simultaneous quantification of urinary 2,8-dihydroxyadenine (DHA) and adenine was optimized efficiently with DoE. The assay has been implemented for clinical diagnosis and therapeutic drug monitoring of patients with adenine phosphoribosyltransferase (APRT) deficiency, which is an inborn error of purine metabolism. Syllabus -- Design of Experiments (DoE) - Get it right from the beginning -- Basic concept and assessment of DoE -- Optimization of LC-MS based clinical assay by DoE 1941

Tuesday 1200 1400

Short Course & Workshop Lunch Mixer @ Steinbeck Foyer 1907

Tuesday 1215 1345

Workshop: Ion Mobility in the Clinical Lab? @ Steinbeck 1 Christopher Chouinard, PhD Clemson University I received my PhD from University of Florida in 2016, where I developed ion mobility-mass spectrometry (IM-MS) methods for steroids and vitamin D metabolites. I then worked as a post-doctoral research at Pacific Northwest National Laboratory, building Structures for Loss Ion Manipulations (SLIM) ion mobility instrumentation for application in metabolomics and proteomics. In 2018, I began my independent career as an Assistant Professor at Florida Institute of Technology. I have since moved to Clemson University in August 2022. Work in my research group focuses on ion mobility-mass spectrometry (IM-MS)-based methods and technology, including structurally selective reactions for improved characterization of steroids and other controlled substances. Financial Disclosures (past 24 months as of Feb 13, 2024) Grants/Research Expenses: MOBILion Systems The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Robin Kemperman, PhD Children’s Hospital of Philadelphia Robin Kemperman received his Bachelor's in chemistry from the HAN University of Applied Sciences in The Netherlands. Thereafter, he fulfilled his MSc and PhD in analytical chemistry at the University of Florida under the direction of Dr. Richard Yost. Currently, he works at the Children's Hospital of Philadelphia as Sr. Mass Spectrometrist in the Metabolic and Advanced Diagnostics Lab. Dr. Kemperman's work has covered a variety of aspects in mass spectrometry, including targeted analysis of steroids and ketone bodies using LC-MS/MS, bile acid, opioid, and glycan isomer separations using ion mobility spectrometry, and metabolomics High-Resolution MS. Dr. Kemperman is experienced in clinical MS-based validations and has presented his work at a variety of national and international meetings. Focusing on the future, he is interested in working on novel innovations for biomedical and clinical applications. Financial Disclosures (past 24 months as of Feb 13, 2024) : none Objective Workshop attendees will learn about the basic operating principles of various ion mobility techniques, the potential benefits and challenges to its routine implementation in the clinical lab, and several potential applications. Summary Ion mobility-mass spectrometry (IM-MS) has become a cornerstone of biomedical analysis, with applications ranging from isomeric small molecule differentiation to the study of protein structure and folding dynamics. Despite its many advantages, IM-MS has yet to see routine implementation in the clinical lab due to challenges in quantitation, limited universal standards, data processing software, and reproducibility across different IMS techniques/vendor platforms. This workshop will introduce the common IMS techniques (e.g., drift tube, traveling wave, FAIMS/DMS, etc.) and their operating principles, expanding upon the benefits of incorporating IMS into conventional LC-MS/MS workflows and discussing the challenges that have limited such incorporation. Finally, an overview of current applications (including metabolomics, lipidomics, and proteomics examples) will be provided. Objective 1: Understand the basic operating principles of IMS and the differences between the different techniques (e.g., drift tube, traveling wave, FAIMS/DMS, etc.) Objective 2: Recognize the benefits and limitations to incorporating IMS into conventional LC-MS/MS workflows in the clinic Objective 3: Become familiar with current (and potentially future) applications of IMS to the clinical lab Syllabus 1. Basic Operating Conditions of IMS: Electric field application, experimental conditions (temperature, pressure, gas composition) 2. Different IMS techniques: Drift tube/traveling wave, field asymmetric/differential mobility, emerging techniques (i.e., TIMS, SLIM, cIMS, etc.) 3. Applications: Current examples from metabolomics, lipidomics, and proteomics 1884

Tuesday 1245 1400

Industry Workshop(s)

No workshops currently booked for this time period.

Tuesday 1400 1425

Welcome Orientation @ De Anza Chris Herold, PhD, MBA MSACL Chris Herold is a scientifically-trained entrepreneur. He received his BS in Chemical Engineering from the University of Virginia, after which he left the US to spend nine months in Lausanne, Switzerland at Scitec SA working on a Perkin Elmer Q-Mass quadrupole to analyze soil and water samples for toxic components. He returned to the US and completed his PhD in Molecular Pathology at the University of California, San Diego (UCSD) and then joined the start-up, Prediction Sciences (PS). While at PS he wrote and directed SBIR grants from the NIH and NSF as Principal Investigator with the goal of identifying correlations between SNP profiles and drug response (pharmacogenomics). He left PS to pursue an MBA from Cornell University and then joined the start-up Arrayomics, which focused on the development of liquid microarray technology. He is a founding board member of MSACL and, as President & COO, has been responsible for its operational logistics since the organization's inception. He is the managing editor of the Journal of Mass Spectrometry & Advances in the Clinical Lab (JMSACL), which is owned by MSACL and published by Elsevier. Financial Disclosures (past 24 months as of Oct 15, 2024) Salary: msacl The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Stephen Master, MD, PhD, FADLM Children's Hospital of Philadelphia Stephen Master received his undergraduate degree in Molecular Biology from Princeton University, and subsequently obtained his MD and PhD from the University of Pennsylvania School of Medicine. After residency in Clinical Pathology at Penn, he stayed on as a faculty member with a research focus in mass spectrometry-based proteomics as well as extensive course development experience in bioinformatics. After time as an Associate Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine in New York City, where he served as Director of the Central Lab and Chief of Clinical Chemistry Laboratory Services, he took a position at the Children's Hospital of Philadelphia at Chief of Lab Medicine. One of his current interests is in the applications of bioinformatics and machine learning for the development of clinical laboratory assays. He would play with R for fun even if he weren't getting paid, but he would appreciate it if you didn't tell that to his department chair. Financial Disclosures (past 24 months as of Nov 08, 2024) Board/Committee: Indigo BioAutomation, Roche Diagnostics The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Tim Garrett, PhD University of Florida College of Medicine Dr. Garrett has over 20 years of experience in the field of mass spectrometry spanning both instrument and application development. He received his PhD from the University of Florida, under Dr. Richard A. Yost, working on the first imaging mass spectrometry-based ion trap instrument. He has also developed MALDI-based approaches to analyze proteins in bacteria and small molecules in tissue specimens. His current interests include the translation of LC-HRMS, MALDI, DESI and LMJSSP in metabolomics to clinical diagnostics. He is an Associate Professor in the Department of Pathology at the University of Florida, and an Associate Director for the Southeast Center for Integrated Metabolomics (SECIM). Financial Disclosures (past 24 months as of Feb 13, 2024) Grants/Research Expenses: Capitainer, Agilent Technologies, ThermoFisher The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Kara Lynch, PhD, DABCC University of California San Francisco Dr. Kara Lynch is a Professor of Laboratory Medicine at the University of California San Francisco, Co-Director of the Core Laboratory at Zuckerberg San Francisco General Hospital and Chemistry Director at UCSF Benioff Children’s Hospital Oakland. She is the co-director of the COMACC-accredited Clinical Chemistry Fellowship Program at UCSF. Her laboratory conducts studies aimed at identifying and quantifying endogenous and exogenous small molecules in biological specimens using novel diagnostic technologies, such as high resolution mass spectrometry, ion mobility mass spectrometry, ambient ionization mass spectrometry and biolayer interferometry. Her lab is involved in translational research studies evaluating the clinical utility of novel biomarkers or biomarker panels to diagnosis, treat and monitor disease. The methods developed in her laboratory are used to investigate perturbations in metabolic pathways caused by disease and drug use and translate the results into information that can be used in clinical practice. Financial Disclosures (past 24 months as of Feb 12, 2024) Grants/Research Expenses: Hound Labs, Restek, Integrated Micro-chromatography Systems, Agilent Technologies, GatorBio The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Alan Rockwood, PhD, DABCC University of Utah, School of Medicine Alan Rockwood, PhD, DABCC is Professor (Clinical) Emeritus of Pathology at the University of Utah School of Medicine in Salt Lake City, Utah, USA. Originally trained in Physical Chemistry, he performed research on the fundamentals of mass spectrometry and instrumentation development before focusing his career on Clinical Chemistry. He became certified by the American Board of Clinical Chemistry and has held a Certificate of Qualification in Clinical Chemistry from the New York State Board of Health. Currently, his primary area of research is the development of mass spectrometry-based quantitative assays for targeted analytes of clinical interest, including small molecules and more recently proteins and peptides. Additionally, he maintains a smaller research effort on fundamentals of mass spectrometry, particularly novel approaches for isotopic profile calculations. He has published >150 papers in peer reviewed journals. Financial Disclosures (past 24 months as of Jul 06, 2024) Expenses/Honoraria: Thermo Scientific The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Cory Bystrom, PhD Ultragenyx Financial Disclosures (past 24 months as of Feb 13, 2024) Salary: Ultragenyx The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Opening Orientation with (1) a brief welcome from Chris Herold, (2) a brief presentation from Stephen Master (President of AACC), (2) an introduction to our new JMSACL co-Editors-in-Chief, Kara Lynch and Tim Garrett (and acknowledgement of founding co-Editors-in-Chief, Alan Rockwood and Michael Vogeser, who brought the journal to this point), and (3) an official welcome from the Chair of the MSACL 2022 Steering Committee, Cory Bystrom. 1908

Tuesday 1425 1445

State of the Science @ De Anza Cory Bystrom, PhD Ultragenyx Financial Disclosures (past 24 months as of Feb 13, 2024) Salary: Ultragenyx The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Michael Angelo, MD, PhD Stanford University School of Medicine Michael Angelo, MD PhD is a board-certified pathologist in the department of Pathology at Stanford University School of Medicine. Dr. Angelo is a leader in high-dimensional imaging with expertise in tissue homeostasis, tumor immunology, and infectious disease. His lab has pioneered the construction and development of Multiplexed Ion Beam Imaging by time of flight (MIBI-TOF). MIBI-TOF uses secondary ion mass spectrometry and metal-tagged antibodies to achieve rapid, simultaneous imaging of dozens of proteins at subcellular resolution. His lab used this technology to discover previously unknown rule sets governing the spatial organization and cellular composition of immune and stromal cells within the tumor microenvironment in triple-negative breast cancer and ductal carcinoma in situ. This effort has led to ongoing work aimed to define broader structural mechanisms that promote tolerogenic niches in cancer, tuberculosis, and the maternal-fetal interface. His lab is expanding this spatial biology framework to leverage new technologies that can map the spatial distribution of transcripts, lipids, and glycans. Dr. Angelo is the recipient of 2014 NIH Director’s Early Independence, 2020 DOD Era of Hope Award and is a principal investigator on multiple extramural awards from the National Cancer Institute, Breast Cancer Research Foundation, Parker Institute for Cancer Immunotherapy, the Bill and Melinda Gates Foundation, and steering committee co-director of the Human Biomolecular Atlas (HuBMAP) initiative. Financial Disclosures (past 24 months as of Jan 30, 2024) : none Kara Lynch, PhD, DABCC University of California San Francisco Dr. Kara Lynch is a Professor of Laboratory Medicine at the University of California San Francisco, Co-Director of the Core Laboratory at Zuckerberg San Francisco General Hospital and Chemistry Director at UCSF Benioff Children’s Hospital Oakland. She is the co-director of the COMACC-accredited Clinical Chemistry Fellowship Program at UCSF. Her laboratory conducts studies aimed at identifying and quantifying endogenous and exogenous small molecules in biological specimens using novel diagnostic technologies, such as high resolution mass spectrometry, ion mobility mass spectrometry, ambient ionization mass spectrometry and biolayer interferometry. Her lab is involved in translational research studies evaluating the clinical utility of novel biomarkers or biomarker panels to diagnosis, treat and monitor disease. The methods developed in her laboratory are used to investigate perturbations in metabolic pathways caused by disease and drug use and translate the results into information that can be used in clinical practice. Financial Disclosures (past 24 months as of Feb 12, 2024) Grants/Research Expenses: Hound Labs, Restek, Integrated Micro-chromatography Systems, Agilent Technologies, GatorBio The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Stefani Thomas, PhD, DABCC, NRCC University of Minnesota Dr. Stefani Thomas is an Assistant Professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota, and the Associate Medical Director of the M Health Fairview University of Minnesota Medical Center West Bank Laboratory. She earned a BA in Biological Sciences from Dartmouth College, a PhD in Pharmaceutical Sciences from the University of Southern California, and she completed a Clinical Chemistry postdoctoral fellowship at Johns Hopkins. Her research program at the University of Minnesota utilizes mass spectrometry-based clinical proteomics for therapeutic and diagnostic biomarker development. Financial Disclosures (past 24 months as of Mar 03, 2024) : none 1939

Tuesday 1445 1500

Break @ De Anza Foyer 1967

Tuesday 1500 1545

Beyond the Human Genome: A Million Person Precision Population Health Project @ De Anza Leroy Hood, MD, PhD Institute for Systems Biology Leroy "Lee" Edward Hood is an American biologist who has served on the faculties at the California Institute of Technology (Caltech) and the University of Washington. He is currently Professor and Chrief Strategy OFficer at the Institute for Systems Biology. Dr Hood has developed ground-breaking scientific instruments which made possible major advances in the biological sciences and the medical sciences. These include the first gas phase protein sequencer (1982), for determining the sequence of amino acids in a given protein; a DNA synthesizer (1983), to synthesize short sections of DNA; a peptide synthesizer (1984), to combine amino acids into longer peptides and short proteins; the first automated DNA sequencer (1986), to identify the order of nucleotides in DNA; ink-jet oligonucleotide technology for synthesizing DNA and nanostring technology for analyzing single molecules of DNA and RNA. Dr Hood believes that a combination of big data and systems biology has the potential to revolutionize healthcare and create a proactive medical approach focused on maximizing the wellness of the individual. He coined the term "P4 medicine" in 2003. Financial Disclosures (past 24 months) : Not reported The vision of this project is that we will develop the infrastructure to employ a data-driven approach to optimizing the health trajectory of individuals for body and brain. We have two large populations (5,000 and 10,000) that have validated this approach for body and brain health, respectively. These studies have led to us pioneering the science of wellness and prevention. This project will require the acquisition of key partners for execution, which will be delineated. We are approaching the Federal Government for funding, as we did for the first Human Genome Project. This project will lead to striking new knowledge about medicine, it will catalyze the initiation of start-up companies and it will catalyze a paradigm shift in healthcare from a disease orientation to a wellness and prevention orientation. This will catalyze the largest paradigm shift in medicine, ever. Moderated by: Daniel Holmes, MD, FRCPC St. Paul’s Hospital 1847

Tuesday 1545 1600

Break @ De Anza Foyer 1968

Tuesday 1600 1645

The Clinical Laboratory Perspective on Wellness Testing: Let’s Take a Look Under the Hood @ De Anza Geoff Baird, MD, PhD University of Washington Geoffrey Baird, M.D., Ph.D., is a board certified pathologist at UW Medicine, and professor and acting chair of Laboratory Medicine and Pathology. He directs the Clinical Chemistry Laboratory at Harborview Medical Center. Dr. Baird’s goal is to provide the highest quality lab services to patients in the UW community and Pacific Northwest region. Dr. Baird earned his M.D. and Ph.D. from UC San Diego. He is board-certified in Anatomic Pathology, Clinical Pathology and Clinical Chemistry. His clinical and research interests include lab test utilization management, proteomics, tissue analysis, general laboratory medicine, pathology and pathophysiology of organ systems and anatomic pathology. Financial Disclosures (past 24 months) : Not reported As medical science continues to make gains in the elucidation of disease pathophysiology and the discovery of cures , some have questioned the value of dedicating dwindling financial resources to maintaining wellness rather than to fighting disease per se. While both approaches are meritorious and complementary, neither approach is alone sufficient to ensure the health of a population. One major problem with the focus on wellness is the Bayesian dilemma that the positive predictive value of clinical laboratory testing in apparently healthy people is often low, as the specificities of few clinical tests are high enough to ensure that most positive results are true. The impact of this dilemma on laboratory-based wellness approaches will be discussed. Moderated by: Daniel Holmes, MD, FRCPC St. Paul’s Hospital 1900

Tuesday 1645 1700

Break @ De Anza Foyer 1969

Tuesday 1700 1800

The Michael S. Bereman Award for Innovative Clinical Proteomics : Seeing the Forest for the Trees: Taking a Step Back to Move Proteomics Forward in the Clinical Lab @ De Anza Mari DeMarco, PhD, DABCC, FACB, FCACB University of British Columbia Mari DeMarco, PhD, DABCC, FCACB, is a Clinical Chemist at Providence Health Care, the Research Director of Providence Research, and a Clinical Associate Professor in Pathology and Laboratory Medicine at the University of British Columbia in Vancouver Canada. Dr. DeMarco completed her PhD in the Biomolecular Structure and Design program at the University of Washington, and a clinical chemistry fellowship at Washington University School of Medicine. With a strong interest in bridging basic biomedical science, analytical chemistry and laboratory medicine, Dr. DeMarco’s research group focuses on building new biofluid tests for direct translation into patient care. A particular area of interest is advancing protein-based clinical diagnostics for neurodegenerative disorders, such as Alzheimer’s disease. The goal of this program of research is to ensure that these new tools make the challenging jump from research into healthcare. Financial Disclosures (past 24 months) : Not reported Sponsored by: Want to run a new test in your clinical lab that takes multiple days to prep, has a complicated (and costly) calibration scheme, and a detection approach so selective it could miss the analyte of interest? If that doesn’t sound appealing, you would be in the majority! While the analytical advantages of mass spectrometry resulted in it decisively displacing ligand binding methods as the gold standard approach for protein quantitation, making progress on the routine testing front has taken additional effort. Here we look at how re-evaluating the status quo in clinical proteomics has helped us take leaps forward and implement protein mass spectrometry to improve patient care. About the Award Moderated by: Christopher Shuford, PhD Labcorp Andy Hoofnagle, MD, PhD University of Washington 1901

Tuesday 1800 2100

Opening Exhibits Reception @ Exhibit Hall - Serra 1848

Tuesday 1900 2000

Mentor Booth Tours @ Exhibit Hall - Serra Meet at Poster #50 1979

2000 2100

Troubleshooting Poster Session @ Exhibit Hall - Serra

20:00 @ poster #28a A Stumbling Block of Harmonizing LC-MS/MS Assays in Clinical Laboratories Hsuan-Chieh (Joyce) Liao University of Washington

20:15 @ poster #28b Morphine and Oxycodone Co-Positivity in Pain Management Urine Drug Testing Stephen Roper Washington University School of Medicine

20:30 @ poster #27a Nonspecific Adsorption and Loss of 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol. Dude, where’s my THC? Triniti Jensen ARUP

20:45 @ poster #27b Interfering Peak in the Estradiol (E2U) LC-MS/MS Assay Mima Geere UCSF

Tuesday 2100 2200

Hospitality Lounge @ Jacks Inside of Jacks Club Room (Portola Hotel) 1849

Wednesday

Wednesday 630

Registration Desk Opens @ De Anza Foyer 1912

Wednesday 700 745

Round Table Interest Groups @ De Anza Foyer (1) On Being a Reviewer with Tim Garrett (2) Follow on discussion about convincing admin that they need to buy a mass spectrometer with Joshua Hayden (3) Shortcomings / Limitations of Antinuclear Antibodies (ANA) : Stark Disparities - Multiplex Vs. Immunofluorescence Assay with Mahesheema Ali (4) Tissue Imaging with Michael Angelo, Laura Sanchez, David Herold 1913

Wednesday 800 855

Glycoproteins as Biomarkers for Cancers @ De Anza Carlito Lebrilla, PhD UC Davis The focus of the group is in the development of analytical tools based on advanced separation and mass spectrometry in two areas—nutrition and diseases. We are developing mass spectrometry based tools for the discovery of markers for cancer including ovarian, breast, and prostate. We are pioneering the glycomic approach for the early diagnosis of cancer. In nutrition we are examining human milk as the model for the perfect food and determining bioactive components in milk. Financial Disclosures (past 24 months) : Not reported The path from fundamental discoveries with MS to translation and commercialization. Moderated by: Laura Sanchez, PhD University of California, Santa Cruz 1855

Wednesday 900 930

How Can Proteomics Fulfill the Unmet Needs of Effective Drug Treatment Stratification for Patients with Ovarian Cancer? @ De Anza Stefani Thomas, PhD, DABCC, NRCC University of Minnesota Dr. Stefani Thomas is an Assistant Professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota, and the Associate Medical Director of the M Health Fairview University of Minnesota Medical Center West Bank Laboratory. She earned a BA in Biological Sciences from Dartmouth College, a PhD in Pharmaceutical Sciences from the University of Southern California, and she completed a Clinical Chemistry postdoctoral fellowship at Johns Hopkins. Her research program at the University of Minnesota utilizes mass spectrometry-based clinical proteomics for therapeutic and diagnostic biomarker development. Financial Disclosures (past 24 months as of Mar 03, 2024) : none The mutational status of a solid tumor can predict the therapeutic efficacy of a specific drug in a molecularly defined subset of patients. Targeted therapies are available to treat advanced (stage II – IV) ovarian cancer with mutations in BRCA1/2 genes. Unfortunately, there is considerable inter-patient heterogeneity in BRCA1/2–based determinations of drug treatment sensitivity. Determining the proteome-level mechanisms of drug treatment sensitivity could enhance our ability to select the ovarian cancer patient populations that would benefit the most from these targeted therapies, consequently improving survival and overall treatment response. Our laboratory is applying mass spectrometry-based proteomics to identify protein signatures of drug treatment sensitivity and subsequent patient stratification for treatment. This presentation will provide an overview of the experimental models and analytical approaches that we are utilizing toward a long-term goal of identifying prognostic protein biomarkers of drug treatment sensitivity in patients with high-grade serous ovarian cancer. Moderated by: Laura Sanchez, PhD University of California, Santa Cruz 1891

Wednesday 930 945

Coffee Break @ Exhibit Hall - Serra 1966

Wednesday 945 1015

N-linked Glycans in Human Disease: From New Tools to Translational and Preclinical Studies @ De Anza Peggi Angel, PhD MUSC Proteomics Center Peggi Angel is Associate Professor at Medical University of South Carolina, where she works on technology advancements in MALDI imaging mass spectrometry (IMS) and biomarker imaging analyses in cancer disparities. Dr. Angel attended graduate school at the University of Georgia’s Complex Carbohydrate Research Center, graduating with a PhD in 2007. Her graduate research was on development of technologies for mapping N-linked glycan sites in mammalian development. After a postdoctoral fellowship at Emory University focused on membrane proteomics of fetal alcohol syndrome, she won a competitive Postdoctoral Fellowship with the Systems-based Consortium for Organ Design and Engineering. With the Fellowship, she worked at Vanderbilt University in the laboratory of Richard Caprioli on methods using MALDI IMS for developmental biology. Dr. Angel has developed IMS methods for increasing sensitivity of protein detection from tissues, analysis and identification of signaling lipids in negative mode, targeted metabolomics on tissue and cell culture, extracellular matrix protein detection in FFPE tissues, and N-glycomic strategies for proteins, cells, and tissue. Dr. Angel is a co-founder of Glycopath, a company that focuses on glycosylation patterns as a prognostic or diagnostic tool. She serves on the board of N-Zyme Scientifics, a company that produces enzymes for mass spectrometry. Dr. Angel is committed to serving the imaging mass spectrometry community and serves as President-Elect for the US Imaging Mass Spectrometry Society. Financial Disclosures (past 24 months as of Feb 16, 2024) Stocks/Bonds: GlycoPath Board/Committee: GlycoPath, N-zyme Scientifics The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. N-glycosylation plays a significant role in immune cell recruitment, influences disease progression and outcome and response to therapy. Here, we discuss simplified workflows capable of reporting N-glycan expression patterns in tissues, cells and biofluids. We present translational and pre-clinical work investigating glycosylation patterns in cardiovascular disease, cancer risk and cancer. A long-term goal is to leverage glycosylation patterns to non-invasively monitor disease status and therapeutic efficacy. Moderated by: Laura Sanchez, PhD University of California, Santa Cruz 1950

Wednesday 1015 1100

Panel Discussion @ De Anza Moderated by: Laura Sanchez, PhD University of California, Santa Cruz 1892

Wednesday 1100 1200

Poster Session @ Exhibit Hall - Serra 1856

Wednesday 1300 1400

Poster Session @ Exhibit Hall - Serra 1860

Scientific Session 1

	Track 1 De Anza 1 Endogenous Small Molecules Chair Brian Keevil University Hospital of South Manchester 2nd Jayson Pagaduan Intermountain Healthcare	Track 2 De Anza 2 Glycomics and Proteomics of SARS-CoV2 Immunology Chair Rebecca Bearden Cleveland Clinic	Track 3 De Anza 3 Taking it to the Top: Reference Methods and Materials Chair Karen Phinney NIST 2nd Andrew T Nelson University of Texas Southwestern	Track 4 Bonzai Practical Training Session CLOSED
1400 1420	Ultrafast Integrated UPLC-MS/MS Second-tier Newborn Screening for Inborn Errors of Propionate, Cobalamin, and Methionine Metabolism Joshua Dubland The University of British Columbia & BC Children’s Hospital	Rational Design of Serological Diagnostics Using Immunoprecipitation-Targeted Proteomic Assays Andrei Drabovich University of Alberta	Internal Standard Approaches: Stable Isotope-labeled Intact, Winged or Peptide Kayla Moehnke Mayo Clinic	CLOSED
1420 1440	Newborn Screening for Vitamin B12 Deficiency: Is it Justified? Is it Possible? Bojana Rakic BC Children’s Hospital, Vancouver, Canada	Afucosylated IgG Responses to BNT162b2 mRNA Vaccine Against Sars-CoV-2 Differ in Naïve and Antigen-experienced Individuals Tamas Pongracz Leiden University Medical Center	Development of a Candidate Reference Measurement Procedure for Urine Albumin Using LC-MS/MS Jesse Seegmiller University of Minnesota	CLOSED
1440 1500	Urine Free Cortisol by LC-MS/MS: Monitoring Known Interferences as Potential Culprits of Iatrogenic Cushing’s Syndrome Julie Ray ARUP Labs	A Targeted Multiplex MRM LC-MS/MS Immunoassay for Characterisation of Antibody Response to SARS CoV2 Vaccination Ivan Doykov University College London	Get Your Reference Right!: Synthesis, Certification, and Confirmation of the First Reference Material for (-)-trans-11-nor-9-Carboxy-Δ9-THC beta-d-glucuronide Raymond Suhandynata University of California, San Diego	CLOSED

Wednesday 1500 1515

Coffee Break @ Exhibit Hall - Serra 1971

Scientific Session 2

	Track 1 De Anza 1 Rapid Detection and Quantitation via Ambient Ionization Chair Vishnu Samara University of Chicago	Track 2 De Anza 2 Tissue imaging - Dynamics and Mapping Chair Peggi Angel MUSC Proteomics Center 2nd James Weatherill The University of Edinburgh	Track 3 De Anza 3 Starting Right - The Life of a Sample from Tube to Bench Chair Michael Chen University of British Columbia	Track 4 Bonzai Practical Training
1515 1535	Rapid Detection of Anticoagulants Using Coated Blade Spray Mass Spectrometry Briana Fitch University of Southern California	Mass Spectrometry Imaging of Glutathione Biosynthesis Heterogeneity Using Multiple Infusion Start Times and IR-MALDESI Allyson Mellinger North Carolina State University	Tracking the Stability of Clinical Blood Plasma Proteins with ΔS-Cys-Albumin—a Dilute-and-shoot LC-MS-based Marker of Specimen Exposure to Thawed Conditions Chad Borges Arizona State University	Oral Fluid as Alternative Matrix for Drug Testing: Clinical Utility and Method Development Adina Badea Lifespan/Rhode Island Hospital & the Warren Alpert Medical School of Brown University
1535 1555	Concomitant Quantification of Methotrexate and its Metabolites in Serum Samples via Fully Automated Coated Blade Spray-Tandem Mass Spectrometry Workflow German Gomez Restek	Mass Spectrometry Histochemistry of Human FFPE Material Getting Ready for the Clinic Peter Verhaert ProteoFormiX	The Decisive Role of Pre-analytical Sample Handling When Investigating the Lipidome in Clinical Research Daniel Kratz Institute of Clinical Pharmacology, Pharmazentrum Frankfurt/Zafes, University Hospital of Goethe-University	... Extended Session ...
1555 1615	Rapid Urine Drug Testing by Direct Analysis in Real-Time (DART)-Mass Spectrometry Ibrahim Choucair Yale School of Medicine	Improving Accuracy and Speed of MALDI MSI for Clinical Translation Sankha (Bobby) Basu Brigham and Women’s Hospital	The Essence of a Streamlined Process for Large-Scale Quantitative Protein Mass Spectrometry Renee Ruhaak LUMC	... Extended Session ...

Wednesday 1615 1630

Coffee Break @ Exhibit Hall - Serra 1972

Scientific Session 3

	Track 1 De Anza 1 Steroids - Methods and Matricies Chair Claire Knezevic Johns Hopkins University	Track 2 De Anza 2 Proteomics - New Methods and Continuous Improvement Chair Mari DeMarco University of British Columbia	Track 3 De Anza 3 Data - Integrating, Mapping and Reporting Chair Patrick Vanderboom Mayo Clinic	Track 4 Bonzai Practical Training
1630 1650	Application of a Novel Steroidomic LC-MS/MS Method for Investigating Metabolic Alterations in Patients with Non-Alcoholic Fatty Liver Disease Federico Ponzetto University of Turin	Proteomic Analyses of Malaria Drug Resistance Annie Moradian Precision Biomarker Laboratories	Data Integration Pipeline for Multi-Batch Untargeted Lipidomics Studies Khyati Mehta Cincinnati Children’s Hospital/University of Cincinnati	Transition Ratio Monitoring for the Masses Russell Grant Labcorp
1650 1710	Ion Mobility-Mass Spectrometry: Targeted Steroid Applications in the Clinical Lab Christopher Chouinard Clemson University	Integrating Lipidomics and Proteomics for Increased Diagnostic Accuracy in Prostate Cancer Lee Gethings Waters	The Chemistry of Our Blood: Mapping Circulating Molecules to the Landscape of Human Health and Disease Nicholas Bevins Sapient Bioanalytics	... Extended Session ...
1710 1730	Salivary Cortisone in the Assessment of the HPA Axis Brian Keevil University Hospital of South Manchester	High Sensitivity Measurement of Thyroglobulin Using Conventional Flowrate LC-MS/MS Mark Kushnir ARUP Institute for Clinical & Experimental Pathology	Using Data Independent Acquisition to Inform the Development of Cerebrospinal Fluid Triple Quadrupole Assays Deanna Plubell University of Washington	... Extended Session ...

Wednesday 1730 1830

Happy Hour in the Exhibit Hall @ Exhibit Hall - Serra 1864

1745 1815

Troubleshooting Posters @ Exhibit Hall - Serra

17:45 @ poster #29a Interfering Compound in Urine Cannabinoid Analysis Agnes Cua Precision Diagnostics

18:00 @ poster #29b Communicating Proteogenomics Data to Physicians John Koomen Moffitt Cancer Center

Wednesday 1830

Dinner on Own @ Off-site Check out one of the many restaurants on Alvarado Street. 1865

Wednesday 1830 1930

Hospitality Reception @ Jacks Inside of Jacks Club Room (Portola Hotel) Meet up with friends for light drinks on your way out to dinner at one of the many restaurants on Alvarado Street. 1977

Wednesday 1845 2200

FeMS Networking Event - Separate Registration Required @ Ferrantes Visit Reg Desk to inquire if interested in participating. 1919

Thursday

Thursday 630

Registration Desk Opens @ De Anza Foyer 1909

Thursday 700 745

Round Table Interest Groups @ De Anza Foyer (1) JMSACL co-Editors-in-Chief (Tim Garrett & Kara Lynch): Current and Interested Editors and Reviewers Round-Up (2) Meet a Clinical Chemist with Shannon Haymond and Stephen Master (3) Tissue Imaging Satellite Conference Discussion with Michael Angelo & David Herold 1914

Thursday 800 855

Proteins in Space: Statistical Approaches to Understand the Spatial Organization and Structure of Proteins in Complex Tissues @ De Anza Barbara Engelhardt, PhD Princeton University Barbara E. Engelhardt, an associate professor, joined the Princeton Computer Science Department in 2014 from Duke University, where she had been an assistant professor in Biostatistics and Bioinformatics and Statistical Sciences. She graduated from Stanford University and received her Ph.D. from the University of California, Berkeley, advised by Professor Michael Jordan. She did postdoctoral research at the University of Chicago, working with Professor Matthew Stephens, and three years at Duke University as an assistant professor. Interspersed among her academic experiences, she spent two years working at the Jet Propulsion Laboratory, a summer at Google Research, and a year at 23andMe, a DNA ancestry service. Professor Engelhardt received an NSF Graduate Research Fellowship, the Google Anita Borg Memorial Scholarship, and the Walter M. Fitch Prize from the Society for Molecular Biology and Evolution. As a faculty member, she received the NIH NHGRI K99/R00 Pathway to Independence Award, a Sloan Faculty Fellowship, and an NSF CAREER Award. Professor Engelhardt’s research interests involve developing statistical models and methods for the analysis of high-dimensional biomedical data, with a goal of understanding the underlying biological mechanisms of complex phenotypes and human disease. Financial Disclosures (past 24 months) : Not reported Spatial single-cell technologies have enabled the comprehensive study of complex tissues and organs at a single-cell level. However, the statistical methods to perform analyses have not kept pace with the technologies for measuring spatially-resolved genes and proteins in tissue samples. In this talk, I will present two methods that allow the study of spatially-resolved proteomics data. First, nonnegative spatial factorization develops a low-dimensional representation of the spatially-resolved samples to identify variation in protein expression across space. Second, Gaussian process spatial alignment allows multiple slices from different technologies to be aligned to a known or unknown common coordinate system, enabling the construction of a tissue atlas from disparate samples of that tissue type. Moderated by: Shannon Haymond, PhD Northwestern University Feinberg School of Medicine 1911

Thursday 855 900

Analytik Jena Industry Brief (5m) @ De Anza MALDI-TOF-MS sample preparation – A comprehensive view of automated liquid handling concepts James Bond 1953

Thursday 900 915

Coffee Break @ Exhibit Hall - Serra 1964

Thursday 915 1000

Statistical Considerations for Biomarker Discovery Experiments: From a Model Organism to Clinical Study @ De Anza Meena Choi, PhD Genentech Extensive experience for the development of statistical methods, tools, and software for the analysis of mass spectrometry-based proteomics and metabolomics data. Highly effective statisticians with over eight years of experience communicating statistical and technical concepts to researchers and clinicians. 5+ years’ experience creating and implementing training programs for chemists, biologists, clinicians and bioinformaticians in Mass Spectrometry-based proteomics community. Financial Disclosures (past 24 months) : Not reported Quantitative mass spectrometry-based proteomics is a technology of growing importance in biological and clinical research. As modern quantitative mass spectrometry-based proteomics workflows become complex and diverse, it requires statistical considerations, methods, and computational tools for experimental planning and data analysis to reduce bias and inefficiencies and maximize the reproducibility of results. This talk will highlight statistics essential for proteomics experiments and considerations for designing a proteomics experiment for biological research biomarker discovery and issues related to large quantitative proteomic datasets generated by diverse types of acquisition of proteomics. Also, this talk will present the comprehensive mass-spectrometry proteomics-based strategy and case studies for the clinical protein biomarker development, from a model organism to large-scale clinical samples, with rigorous experimental design and statistical analysis. Moderated by: Shannon Haymond, PhD Northwestern University Feinberg School of Medicine 1875

Thursday 1000 1015

Coffee Break @ Exhibit Hall - Serra 1965

Thursday 1015 1100

Adapting to the New Normal: Navigating the Rollercoaster of SARS-CoV-2 Testing Needs While Building Long Term Capabilities @ De Anza Patrick Mathias, MD, PhD University of Washington Patrick Mathias, M.D., Ph.D., is a board-certified clinical pathologist and Associate Director of Informatics for UW Laboratory Medicine. Lab medicine has large impact on the general practice of medicine. It is key to correctly diagnosing diseases and selecting the right treatments for patients. Dr. Mathias's goal is to combine technical and medical knowledge to fulfill the triple aim--reduce the per capita cost of health care, improve the health of populations and most importantly improve the patient experience of care. Dr. Mathias earned his M.D. and Ph.D. from the University of Illinois. His clinical and research interests include clinical informatics, clinical chemistry and molecular diagnostics. Financial Disclosures (past 24 months as of Feb 13, 2024) : none The COVID-19 pandemic has been a challenging time for clinical laboratories, but it has also improved awareness of the important role labs play across health care and public health domains. The University of Washington Department of Laboratory Medicine and Pathology has worked to establish diagnostic SARS-CoV-2 testing as a widely available resource over a large footprint of our state by combining expertise in laboratory testing and informatics with community partnerships to expand testing access and convenience. Over the course of the pandemic the needs of our laboratories as well as of the public and of public health authorities have evolved. Staffing and supply chain challenges have placed a greater emphasis on efficiency and productivity. The need for genomic surveillance of the evolving virus has required a close integration of clinical workflows with research-focused genomics workflows. Increased demand for services coupled with record high positivity rates during the omicron surge has challenged our model for expanding capacity using sample pooling. This presentation will describe the evolution of our testing program and infrastructure amidst these challenges, highlighting the informatics capabilities we needed to adapt. Finally, we will discuss what needs and capabilities are likely to persist beyond the pandemic and how the lessons we have learned can better equip laboratories to improve the health of the public. Moderated by: Shannon Haymond, PhD Northwestern University Feinberg School of Medicine 1961

Thursday 1100 1200

Poster Session @ Exhibit Hall - Serra 1869

Thursday 1300 1400

Poster Session @ Exhibit Hall - Serra 1870

Thursday 1400

Exhibits Closed @ Exhibit Hall - Serra 1874

Scientific Session 4

	Track 1 De Anza 1 Microbiology - Identification and Metabolomics Chair Jeff Whitman UCSF	Track 2 De Anza 2 Monitoring mAb Chair Ruben Y. Luo Stanford University 2nd Rashmi Kumar Stanford University	Track 3 De Anza 3 Making the Most of the Data We Harvest Chair Paula Ladwig Mayo Clinic 2nd Jennifer Kemp Mayo Clinic	Track 4 Bonzai Practical Training
1400 1420	Identification of the Subspecies from Mycobacterium Abscessus Complex by MALDI-TOF MS and Machine Learning Approach David Rodriguez-Temporal Hospital General Universitario Gregorio Marañón, Madrid, Spain View Slides (PDF)	Therapeutic Antibody Monitoring: the Case of Infliximab Maria Willrich Mayo Clinic	Development and Implementation of a Web-based Application for Urine Drug Testing and Improving Resulting Workflow Abed Pablo University of Washington	Working Smarter Not Harder on Sample Prep Matthew Crawford Labcorp
1420 1440	Unique Chemical Biology Tools for Metabolomics Analysis – Exploring Gut Microbiota Metabolism Daniel Globisch Uppsala University	Development and Validation of a Bioanalytical Method for Certolizumab Pegol (Cimzia) Drug Using Surface Plasmon Resonance Brett Holmquist Labcorp	Machine Learning-based Fragment Selection Improves Performance of Qualitative PRM Assays for Viral Pathogen Screening Patrick Vanderboom Mayo Clinic	... Extended Session ...
1440 1500	Investigating Microbial Cooperation and Metabolic Communication During Clostrioles Difficile Infection Using Imaging Mass Spectrometry Boone Prentice University of Florida	Measurement of Therapeutic and Anti-drug Antibodies Using Biolayer Interferometry Kara Lynch University of California San Francisco	Isotopic Distribution Calibration for Mass Spectrometry Anthony Maus Mayo Clinic	... Extended Session ...

Thursday 1500 1515

Break @ De Anza Foyer 1973

Scientific Session 5

	Track 1 De Anza 1 Vitamin D Chair Julie Ray ARUP Labs 2nd Amol Bajaj ARUP	Track 2 De Anza 2 Drugs of Abuse Chair Melissa Budelier TriCore Reference Laboratories 2nd Imir Metushi UCLA	Track 3 De Anza 3 Late-Breaking Submissions A Chair Kamisha Johnson-Davis University of Utah and ARUP	Track 4 Bonzai Practical Training
1515 1535	Learning from Vitamin D Binding Protein Andy Hoofnagle University of Washington	Analysis of Suspected Opioid Overdose Samples Using High Resolution Mass Spectrometry (HRMS) for Public Health Opioids Biosurveillance Program in South Carolina James LaPalme SC PHL	Detection of Mycobacterial from Species to Sub-strain Level with Pathogen-derived Peptidomes Tony Hu Tulane University School of Medicine	Introduction to Clinical Proteomics Using Mass Spectrometry Timothy Collier Quest Diagnostics
1535 1555	Free 25-hydroxy Vitamin D Measured by LC-MS/MS in Healthy Adults and Individuals with Kidney Disease Mark Kushnir ARUP Institute for Clinical & Experimental Pathology	Opioid Overdose Harm Reduction Drug Checking and Illicit Drug Supply Surveillance by On-site Paper Spray Mass Spectrometry (PS-MS) Chris Gill Vancouver Island University	Novel First Trimester Biomarkers of Fetal Growth Restriction Identified by Next Generation Proteomics of Maternal Plasma Nandor Gabor Than Research Centre for Natural Sciences, Budapest, Hungary	... Extended Session ...
1555 1615	Clinical Utility of Measuring the Vitamin D Metabolome including 24,25-(OH)2D3 by LC-MS/MS Martin Kaufmann Queen’s University	Opiate Drug Testing Does Not have to be a “pain in the MLS”: How a Second-generation LC-MS/MS Assay Improved Workflow for Drug Testing and Sign-out Hsuan-Chieh (Joyce) Liao University of Washington	Precise Quantitation of PTEN by Immuno-MRM: A Tool to Resolve the Breast Cancer Biomarker Controversy Christoph Borchers Jewish General Hospital, McGill University Montreal, QC, Canada	... Extended Session ...

Thursday 1615 1630

Break @ De Anza Foyer 1974

Scientific Session 6

	Track 1 De Anza 1 Multiplexing Small Molecules and Glycans Chair Allyson Mellinger North Carolina State University	Track 2 De Anza 2 Top-Down Protein Characterization Chair Timothy Collier Quest Diagnostics	Track 3 De Anza 3 Late-Breaking Submissions B Chair Gwen McMillin University of Utah and ARUP 2nd Danting Liu Mayo Clinic	Track 4 Bonzai Practical Training
1630 1650	Targeting Cellular Nucleotide Biosynthesis Using Ultrahigh-Performance Liquid Chromatography Coupled with High Resolution Mass Spectrometry Xueheng Zhao Cincinnati Children’s Hospital Medical Center	Discovery of a Biomarker for beta-Thalassemia by Fourier Transform Ion Cyclotron Resonance Mass Spectrometry and Proton Transfer Reaction- Parallel Ion Parking Yuan Lin Florida State University	Mitochondrial and Metabolic Dysfunctions in Neurons Carrying the 22q11.2 Deletion Wojciech Michno Stanford University / University College London	Free Climb or Free Solo: Guidance and Accounts of Establishing Reference Intervals for LDT Mass Spectrometry Assays Elizabeth Frank, Kelly Doyle University of Utah Health / ARUP Laboratories
1650 1710	Tumor Associated Carbohydrate Antigens (TACAs) as Promising Targets for the Development of Immunotherapy for Colorectal Cancer Katarina Madunić Leiden University Medical Centre	Capillary Zone Electrophoresis Coupling with High-resolution Mass Spectrometry for Top-down Structural Characterization of Hemoglobin Variants Ruben Y. Luo Stanford University	Correlation of Genotyping and Phenotyping with the IGF-1 assays for Growth Hormone disorders Ravinder Singh Mayo Clinic	... Extended Session ...
1710 1730	Serum Bile Acid Profiling by UHPLC-MS/MS Predicts Cholesteric Pruritus Reduction in Maralixibat Treated Patients with Bile Salt Export Pump Deficiency Kenneth Setchell Cincinnati Children’s Hospital Medical Center	Detection of an Unusual IGF-2 Species Using High-resolution Mass Spectrometry During a Routine IGF-1 Clinical Assay Ievgen Motorykin Quest Diagnostics	Mapping the 3 D Proteome Using Surface Accessibility in Animal Models of Disease John Yates Scripps Research Institute	... Extended Session ...

Thursday 1745 2000

Dinner & British-Style Trivia Night with Tim @ San Carlos 1943

Thursday 2000

After Hours Activity Suggestions @ Off-site *These are non-MSACL-sponsored activities. Alvarado Beer Garden. Club Cibo - $5 drinks all night. 1917

Friday

Friday 700 800

Monterey Challenge Run/Walk @ De Anza Foyer Meet-up in front of Registration in De Anza Foyer. Advice: Once on path, go left towards Cannery Row. 1878

Friday 800

Registration Desk Opens @ De Anza Foyer 1910

Friday 900 1000

Addressing Hurdles in Clinical Translation of Targeted Proteomics @ De Anza Jeffrey Whiteaker, PhD Fred Hutchinson Cancer Research Center Financial Disclosures (past 24 months) : Not reported Quantifying proteins and post-translational modifications will improve precision medicine, but several hurdles remain to adopting proteomics to the clinical laboratory. Dr. Whiteaker will discuss successes and remaining challenges for incorporating targeted proteomic measurements in clinical trials and other clinical applications. Moderated by: Stefani Thomas, PhD, DABCC, NRCC University of Minnesota Timothy Collier, PhD Quest Diagnostics 1879

Friday 1000 1030

Newborn Screening by Mass Spec Meets Newborn Screening by DNA Sequencing @ De Anza Michael Gelb, PhD University of Washington Michael H. Gelb is Professor of Chemistry and Barbara L. Weinstein Endowed Chair in Chemistry, Adjunct Professor of Biochemistry at the University of Washington. Major developments in the Gelb lab include discovery of protein prenylation, development of ICAT proteomic reagents, identification of phospholipases involved in lipid mediator generation, development of anti-parasite drugs, and development of mass spectrometry for newborn screening. Awards include: Repligen Award in Chemistry of Biological Processes (Amer. Chem. Soc.), Univ.of Washington Faculty Lecture Award, Gustavus John Esselen Award (Harvard Univ.), AAAS Fellow, NIH Merit Award, Medicines for Malaria Project of the Year Award, Pfizer Award in Enzyme Chemistry, ICI Pharmaceuticals Award for Excellence in Chemistry. The Gelb lab has published more than 500 papers and 100 patents in biological chemistry. The Gelb laboratory has developed mass spectrometry for worldwide newborn screening of lysosomal storage diseases (the latest expansion of newborn screening panels). Financial Disclosures (past 24 months) : Not reported Our laboratory has been developing tandem mass spectrometry (MS/MS) for worldwide expansion of newborn screening (NBS) panels to include an ever-increasing collection of treatable genetic diseases. There is widespread discussion on the use of whole genome and whole exome DNA sequencing in population-wide NBS. The intersection of biochemical- and DNA-based NBS is an interesting topic now under heavy discussion. We will highlight the development of liquid chromatography-MS/MS (LC-MS/MS) for multiplex NBS of a large panel of treatable genetic diseases in newborns. Next generation sequencing (NGS) is also employed currently as a second-tier analysis after LC-MS/MS assays. We will also illustrate how it is possible to carry out first-tier NGS followed by second-tier LC-MS/MS NBS. LC-MS/MS is used together with enzyme substrates and biomarkers to monitor the activity of a large collection of enzymes and to measure the abundance of biomarkers in dried blood spots on NBS cards. We will focus on multiplex methods and then zoom in one a more detailed analysis of one disease called metachromatic leukodystrophy (MLD). We carried out a pilot MLD NBS study and determined that the rate of false positives out of 28,000 newborns screened is essentially zero showing the power of LC-MS/MS for NBS of this lysosomal storage disorder. In the second arm of the study, we have been measuring the activity of the enzyme relevant to MLD on a large collection of gene variants that are found in allele databases and for which no pathogenic information is reported. We show how we can integrate these efforts to provide for a highly efficient NBS program for MLD. We screened ~28,000 newborns for elevated sulfatide lipid, the biomarker that is relevant to MLD and found 180 high sulfatide newborns. These were submitted to an assay of the activity of the relevant enzyme, arylsulfatase A, and all but two showed normal levels of activity. DNA sequencing was carried out on 2 newborns, one with 0% and one with 8% of normal ARSA activity. The newborn with 0% activity was confirmed to have MLD, the other was shown to not have MLD. On the DNA front, we created a phenotype matrix that allows one to input the ARSA enzymatic activity of each variant to provide a composite genotype, and to make a prediction of the phenotype associated with this genotype. We show that this method is 83% accurate at predicting the true set of phenotypes observed in MLD patients. Massively multiplexed NBS of genetic diseases in newborns is possible using LC-MS/MS, and when used with second-tier NGS leads to a successful NBS platform. We show that it is also possible to carry out NGS as a first-tier NBS step and to clarify the results with second-tier biochemical assays based on LC-MS/MS. Thus LC-MS/MS meets DNA and DNA meets LC-MS/MS, and this provides a framework for the future employment of both LC-MS/MS and NGS in expansion of population based NBS. Moderated by: Stefani Thomas, PhD, DABCC, NRCC University of Minnesota Timothy Collier, PhD Quest Diagnostics 1880

Friday 1030 1050

Coffee Break @ De Anza Foyer 1963

Friday 1050 1120

Utilization of Mass Spectrometry to Discover and Develop Novel Biomarkers to Support Drug Development @ De Anza Veronica Anania, PhD Genentech Experienced researcher with Ph. D. in Molecular and Cell biology with over 10 years experience in immunology, protein biochemistry, and methods development. Strong neuroimmunology biomarker strategist and mass spectrometry group leader. Financial Disclosures (past 24 months) : Not reported Biomarkers play an important role in the drug development process including providing necessary insights into target engagement, dose selection and mechanism of action of candidate therapeutics. LC-MS is uniquely positioned to enable accurate quantitation of both small and large molecule biomarker candidates, however, the process of going from biomarker discovery to a multiplexed targeted MRM panel in clinical samples is long and resource intensive. Moreover, biomarker candidates often fail to replicate when tested in large clinical cohorts. Recent advances in data-independent MS (DIA-MS) have made this technology more accessible and certain benefits of DIA-MS including reproducible label-free analysis of hundreds of samples, ability to capture low abundance ions over a high dynamic range, and deep proteome coverage makes this technology well suited to streamline translational proteomics. One major hurdle for using DIA-MS to support drug development is that the quantitative range for most DIA-MS methods has not been well characterized and thus, quantitative conclusions drawn by prior studies that have employed this approach have been controversial. Here, we describe challenges associated with applying DIA-MS methods to address questions associated with clinical development and introduce best practices for establishing quantitative criteria for DIA-MS approaches in clinical trial samples. Results and lessons learned from both discovery and targeted clinical biomarker studies will be discussed and a model for a more streamlined biomarker development workflow that conserves resources and provides more comprehensive proteomic information from clinical trial samples will be discussed. Moderated by: Stefani Thomas, PhD, DABCC, NRCC University of Minnesota Timothy Collier, PhD Quest Diagnostics 1948

Friday 1120 1155

Panel Discussion @ De Anza Moderated by: Stefani Thomas, PhD, DABCC, NRCC University of Minnesota Timothy Collier, PhD Quest Diagnostics 1881

Friday 1155 1200

Closing Statements @ De Anza 1949

Friday 1200 1400

Boxed Lunch Pick-Up and Mixer @ Jacks Pickup a boxed lunch and enjoy a little down time or check out the workshop starting in Bonsai at 1215. 1882

Friday 1215 1345

Workshop: Rethinking the Traditional Workflow for Urine Toxicology Testing @ Bonsai Melissa Budelier, PhD TriCore Reference Laboratories Dr. Budelier the Medical Director of Clinical Chemistry and Toxicology at TriCore Reference Laboratories and Clinical Assistant Professor of Pathology at the University of New Mexico. Her research interests are broadly focused on developing clinically useful, mass spectrometry-based assays to improve diagnosis and treatment of human disease. Her expertise are in Toxicology/TDM, assay development and validation, and protein quantification. Financial Disclosures (past 24 months as of Feb 13, 2024) Expenses/Honoraria: Waters, Roche Diagnostics Royalties: Multiplexed MS Assay patents The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Benjamin Beppler TriCore Reference Laboratories Financial Disclosures (past 24 months) : Not reported Objectives - Identify common challenges with reflexive urine drug screening - Discuss the utility of 'hybrid' testing and direct to definitive testing using mass spectrometry - Address the importance of drug panel test selection, and the potential issues with specific drug classes - Describe the value of providing interpretive reports for urine drug testing, particularly for pain management clients Workshop Summary Many clinical laboratories continue to utilize a traditional urine drug testing algorithm involving an initial screen, typically via an automated immunoassay, followed by confirmation of positive and/or unexpected results using mass spectrometry. This algorithm emerged in the 1970s and 1980s from the desire to test for the use of illicit substances in the military and other workplaces. It was designed to answer the question: Are employees upholding a drug-free workplace? This algorithm presents significant limitations in many clinical situations, particularly in the areas of pain management and substance use disorder treatments, where the primary question changes to: Is my patient taking their medication as prescribed? This workshop will discuss several alternatives for urine drug testing, such as direct to mass spectrometry testing and 'hybrid' panels. It will also discuss considerations for selecting the appropriate analytes for urine drug testing panels and potential pitfalls associated with certain classes of drugs. Finally, it will introduce our recent efforts to implement the use of interpretive reporting for pain management clients. 1940

Friday 1400 1700

Workshop: Pre-analytical considerations as prerequisite for successful clinical application of lipidomics @ De Anza 1 Robert Gurke, PhD Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Robert Gurke received his diploma in chemistry at the Humboldt-University zu Berlin, Germany in 2012 followed by his doctoral thesis at the Technische Universität Dresden in 2016. After a short period as study director in a GLP-compliant bioanalytical company in Berlin he started working as research associate at the Institute of Clinical Pharmacology as well as the Fraunhofer ITMP in Frankfurt under the guidance of Prof. Geisslinger. Robert Gurke is head of the LC-MS analytics group in both institutions since 2021. Mr Gurke is performing LC-MS/MS analysis since starting his doctoral thesis and gained broad experience in the field of developing and validating methods for the determination of exogenous and endogenous small molecules in different complex matrices. Financial Disclosures (past 24 months) : Not reported Bo Burla, PhD Sling @ National University of Singapore I studied biology at the University of Zurich, Switzerland, and made my PhD in Molecular Plant Physiology in the lab of Prof. Enrico Martinoia, focusing on ABC transporters and comparative molecular phylogenetics. Subsequently, I became as researcher at the University Hospital of Zurich, where I was involved in establishing an LC/MS-based assay for the peptide hormone hepcidin and in projects studying Fabry Disease mechanisms. Biological processes, bioanalysis, clinical applications and the use of informatics to improve workflows have been my constant research interests. With this background I am now working as a senior researcher at the Singapore Lipidomics Incubator (SLING), heading our new data team that is focusing on developing workflows and software pipelines for the analytical data processing, QA/AC and exploration of the diverse lipidomics datasets generated by our lab. Financial Disclosures (past 24 months) : Not reported Margret Thorsteinsdottir, PhD University of Iceland Professor in Pharmaceutical Analytical Chemistry at the Faculty of Pharmaceutical Sciences, University of Iceland and R&D Director of ArcticMass LTd, Reykjavik, Iceland. Dr. Thorsteinsdóttir received her PhD from Uppsala University, Sweden in 1998. From 2000 to 2009 she was the managing director of Bioanalytical Laboratories at deCODE Genetics, Reykjavik, Iceland. She has extensive experience in development of analytical methods for metabolite profiling and quantification of clinical biomarkers in various biofluids utilizing chemometrics with the goal of improved clinical management of patients towards personalized patient care. Her current research interest includes studies of lipid metabolism in cancer cells and profiling plasma derived biomarkers for early detection of BRCA-related breast cancer. She is responsible for implementation of clinical mass spectrometry for support of diagnostics and therapeutic drug monitoring in collaboration with ArcticMass and the Landspitali University Hospital, Reykjavik, Iceland with major focus on quantitative targeted proteomics for clinical diagnosis. She is a principal investigator of the Icelandic Research Rannis projects, profiling metabolites for breast cancer diagnosis and search for novel biomarkers for early breast cancer diagnosis by metabolomics. Dr. Thorsteinsdóttir is a principal investigator for the Marine Biotechnology ERA-net project CYNOBESITY and the Horizon 2020 project MossTech, with the main task to isolate, identify and structurally characterize bioactive compounds from cyanobacteria, Icelandic mosses and liverworts. She is one of the founders of Females in Mass Spectrometry (FeMS), she is a vice-leader of the working group clinical significance and applications of (epi)lipidomics in the pan-European network, EpiLipidNET and vice-chair of the Nordic Metabolomics Society. Financial Disclosures (past 24 months as of Jul 11, 2024) : none Anne K. Bendt, PhD Singapore Lipidomics Incubator (SLING), National University of Singapore Anne K Bendt studied Biology focusing on marine biotechnology (Greifswald University, Germany), followed by a PhD in Biochemistry (Cologne University, Germany) employing proteomics and transcriptomics. Driven by her fascination for infectious diseases, she joined the National University of Singapore (NUS) in 2004 to develop lipidomics tools for tuberculosis studies. She is now a Principal Investigator at the Life Sciences Institute, NUS, focussing on translation of mass spec technologies into clinical applications, and serving as the Deputy Director of the Singapore Lipidomics Incubator (SLING) taking care of operations and commercialization. Financial Disclosures (past 24 months as of Feb 13, 2024) : none Objectives It is the objective of the workshop to provide an introduction into pre-analytical considerations for clinical application of MS-based analytics, with a special focus on lipids. However, these considerations are in many cases independent of specific analytes of interest and can hence be applied for polar metabolites as well as proteins. The workshop is focused on main hurdles to be considered when performing clinical research using LC-MS based determination of lipids namely: (I) pre-analytical sample handling, (II) frequent generation of patient samples as well as (III) overall cohort and study design. Summary Lipids are involved in a broad spectrum of functionalities in the organism and implicated in a variety of physiological and pathological processes. Changes in lipid levels are promising biomarkers for early diagnosis, prognosis of disease progression, or guidance for selecting promising therapeutic approaches. However, biomarker discovery in the field of lipidomics is a very challenging process since lipids require specific procedures regarding sampling (including selection of sample type and collection procedures, storage conditions and number of freeze-thaw cycles), sample preparation and analysis for reliable determination. As especially pre-analytical sample handling is a critical step for the reliable analysis of the lipidome, a close cooperation with the clinicians is necessary. This ensures following a highly standardized protocol for venous blood sampling to avoid several pre-analytical pitfalls potentially changing the lipid profile ex vivo. As collecting venous blood samples is very laborious for patients as well as clinicians, other ways for a more frequent sample collection are necessary. Therefore, capillary blood sampling using microsampling devices is an auspicious way to complement the strategy of analyzing venous blood-based samples taken in the clinics. Besides considering the right sampling strategy, the structured recording of sampling details and subject metadata, the overall planning of the study and also the cohorts to be included is of high relevance. All mentioned points have to be considered before starting a clinical research project applying lipidomics to generate high quality data making biomarker discovery possible. Syllabus - Pre-Analytical factors influencing lipid concentrations - Capillary vs. venous blood sampling - the potential of microsampling - Cohort & Study design for lipidomics in clinical research 1883

Friday 1400 1800

Short Course: LC-MSMS 201 : Understanding and Optimization of LC-MS/MS to Develop Successful Methods for Identification and Quantitation in Complex Matrices @ De Anza 2 Robert Voyksner, PhD LCMS Limited Dr. Robert D. Voyksner received his B.S. in Chemistry at Canisius College in 1978 and his Ph.D. at the University of North Carolina at Chapel Hill in 1982. He was employed at Research Triangle Institute (RTI) from 1983-2001 as the director of the mass spectrometry facility and has been responsible for developing extraction, separation and mass spectrometric methods for biologically and environmentally significant compounds. His work earned him the Presidents Award, the highest award within RTI. In 2001 he co-founded LCMS Limited in Durham, NC and has been the CEO of the company to date. Under his direction LCMS Limited is working on technological advancements in LC-MS/MS, offering services to pharmaceutical, clinical and agrochemical industry for solving unique problems by LC/MS/MS and offering training in LC/MS/MS and MS/MS interpretation and on LC/MS/MS instrumentation. Dr Voyksner is also an Adjunct professor at the North Carolina a School of Veterinary Medicine and at The University of North Carolina School of Pharmacy. Dr. Voyksner's research in mass spectrometry has resulted in over 230 publications and presentations, primarily in the area of LC-MS/MS. He has served on the Board of Directors for The American Society For Mass Spectrometry (ASMS), is on the organization committee for The Montreux LC/MS Symposium and was the organizer for the 1995, 1999, 2003 and 2007 Montreux LC/MS Symposia. Dr. Voyksner has taught over 100 courses on LC-MSMS, CE/MS and CID interpretation during the past 10 years for MSACL, ASMS, pharmaceutical companies; ISSX, PBA, HPCE and HPLC focused meetings. Financial Disclosures (past 24 months as of Feb 13, 2024) Consultancy: Aimmune, Kenner Pharma, Clearwater cancer inst, Vast pharma, Gensenta The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. ** Part In-Person and Part Online ** This is the first segment (4 hr) of a 16 hour, part in-person and part online, short course. Segments 2, 3 and 4 will take place ONLINE on April 22-24, 2022. While attending this IN-PERSON segment is FREE, the ONLINE attendance is fee-based. You can REGISTER HERE. ---------- This course is designed for the chromatographer / mass spectrometrist who want to be successful in developing methods, method optimization and solving problems using LC/MS/MS. The course covers the atmospheric pressure ionization (API) techniques of electrospray, pneumatically assisted electrospray and atmospheric pressure chemical ionization (APCI) and atmospheric pressure photo ionization (APPI) using single quadrupole, triple quadrupole, time-of-flight and ion trap mass analyzers. Discussions of sample preparation and chromatography will target method development and optimization for the analysis of "real-world" samples by LC/MS/MS. The course highlights the following topics with respect to optimization a method to achieve the best sensitivity, specificity and sample throughput: Optimization ionization in API techniques, understanding and minimizing matrix suppression, relative merits of various LC column lengths, particle sizes and column diameters for LC/MS/MS analysis, introduction into the interpretation of MS/MS spectra, important issues in LC/MS/MS quantitation, and optimization of an quantitative analysis. Applications of LC/MS/MS to analyze compounds of clinical interest in biological matrices will be discussed throughout the course to emphasize the topics covered. 1904

Friday 1400 1800

Workshop: CLSI C64 - Supporting development of quantitative protein and peptide assays for clinical use @ De Anza 3 Cory Bystrom, PhD Ultragenyx Financial Disclosures (past 24 months as of Feb 13, 2024) Salary: Ultragenyx The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Russell Grant, PhD Labcorp Dr. Grant earned a first-class honors degree in Industrial Chemistry from Cardiff University and a PhD in Chromatographic and Mass Spectrometric technologies from the University of Swansea, Wales, United Kingdom. He continued his scientific training in various industrial settings, which have included senior scientist at GSK, Principal scientist at Cohesive Technologies, Technical director at Eli Lilly, and Director of Mass Spectrometry at Esoterix Endocrinology. Dr Grant is currently the Vice President of Research and Development and co-discipline director for Mass spectrometry at Labcorp. Dr Grant has pioneered the use of direct injection technologies, chromatographic systems multiplexing, microsampling, utility of automation, and other new analytical platforms in direct patient care. His research goals are focused upon improvements in speed, sensitivity, and quality of liquid chromatography with tandem mass spectrometric (LC-MS/MS) analytical systems and assays. Dr Grant has been awarded 100 patents and received both the MSACL Distinguished contribution award and ASMS AL Yergey “Unsung Hero” Award in 2024 for his contributions to Clinical Diagnostics using Mass Spectrometry. Financial Disclosures (past 24 months as of Oct 09, 2024) Consultancy: HepQuant Stocks/Bonds: LabCorp Salary: LabCorp The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. * with Special Guest Stars * Objective: Workshop attendees will gain an understanding of the clinical assay development framework for proteins and peptides established in CLSI C64. Using C64 as a framework for development will help the laboratorian approach protein and peptide assay development confident that analytical performance will meet clinical requirements. Summary: The development and validation of quantitative assays for proteins and peptides for clinical use is a significant undertaking and presents challenges that are distinct from small molecules. The heterogeneous nature of proteins and the frequent requirement to use proteolysis aided workflows add complexity that require careful attention to definition The workshop will be an interactive discussion covering each chapter in C64, guided by authors that contributed extensively to the development of the document. Objective 1: Understand the holistic process of delivering a clinically relevant LC-MS/MS protein/peptide assay from inception to validation. Objective 2: Recognize the factors in assay development that are unique to proteins and peptides in comparison to traditional small molecule assays. Objective 3: Understand key experimental requirements for successful development and validation. Syllabus: 1. Introduction to C64, philosophy and scope 2. Interactive discussion of each chapter 1885

Friday 1400 1800

Short Course: Sample Prep 201 : Sample Preparation and Alternative Matrices for LC-MS Assays @ Bonsai William Clarke, PhD, MBA, DABCC Johns Hopkins University School of Medicine Dr. Clarke received his Ph.D. in Analytical Chemistry from the University of Nebraska in Lincoln in 2000, followed by a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine, ending in 2002. In addition, he received an MBA focused on medical services management from the Carey School of Business at Johns Hopkins in 2007. Following his post-doctoral fellowship, he remained at Johns Hopkins, where he is a Professor in the Department of Pathology, as well as the director of Point-of-Care Testing, Reference Toxicology, and Phlebotomy for the hospital. He also serves as the Vice-Chair for Quality and Regulatory Affairs in the Department of Pathology. His research interests include clinical mass spectrometry, method development and evaluation for therapeutic drug monitoring, clinical toxicology, point-of-care testing, and development/validation of biomarkers for use in drug management. Dr. Clarke has published as author or co-author over 170 peer-reviewed manuscripts or book chapters, and is the Co-Editor of the textbook Contemporary Practice in Clinical Chemistry. Financial Disclosures (past 24 months as of Feb 13, 2024) Consultancy: Roche Grants/Research Expenses: Thermo Fisher, Danaher, Roche Board/Committee: Roche, Truvian The presenter will not mention or discuss Specific Products or Services of the company(ies) or technology listed above, or of ANY other ineligible entity, except in general, generic terms ensuring balance and impartiality. Mark Marzinke, PhD, DABCC, FAACC Johns Hopkins University School of Medicine Dr. Mark Marzinke is Professor of Pathology and Medicine in the Johns Hopkins University School of Medicine. He is board-certified in Clinical Chemistry by the American Board of Clinical Chemistry. He serves as the Director of the General Chemistry Laboratory at the Johns Hopkins Hospital and the Clinical Pharmacology Analytical Laboratory within the Division of Clinical Pharmacology. Dr. Marzinke is Co-Principal Investigator (PI) of the HIV Prevention Trials Network (HPTN) Laboratory Center (LC) and is the Director of the Clinical Laboratory Core for the Johns Hopkins Center for AIDS Research. His primary research interests are in the areas of antiretroviral pharmacology, HIV prevention science, mass spectrometry, pharmacogenetics and precision medicine, and laboratory automation. Dr. Marzinke has an active research program and serves as a principal investigator (PI) or co-investigator on a number of grants. He has collaborated on research to better characterize the multi-compartment pharmacology of antiretroviral agents when administered using alternative drug delivery systems using liquid chromatographic-mass spectrometric approaches. He has published more than 180 peer-reviewed articles, and holds leadership positions in several societies. Financial Disclosures (past 24 months) : Not reported ** Part In-Person and Part Online ** This in-person activity is Segment 2 (4 hr) of a 3 segment (12 hour total), part in-person and part online, short course. Segments 1 and 3 will take place ONLINE on March 4 & April 22, 2022. The first segment is before the conference, the third segment is after the conference. While attending this IN-PERSON segment is FREE, the ONLINE attendance is fee-based. You can REGISTER HERE. ---------- This course highlights not only the importance of sample processing in the clinical laboratory environment, but also illustrates the "fit for purpose" application of processing techniques in clinical mass spectrometry. This course discusses the theory behind different specimen preparation methods, strengths and weaknesses of each approach, as well as opportunities for automation. The first 4 hour online segment will cover workshop ground rules, introduction, pain points of LC-MS, specimen processing (tube types, management, etc.), and matrix effects. The second 4 hour in-person segment will cover dilution and protein precipitation, solid phase extraction, supported liquid extraction, liquid-liquid extraction, and affinity-based sample preparation The third 4 hour online segment (online) will elaborate on the foundations established in the first two segments, and expand into newer technologies and automated alternatives for sample processing. Specific topics to be covered include: Pain points in clinical LC-MS Overview of specimen processing in laboratory medicine Off-line sample processing On-line sample processing Analysis of blood and urine LC-MS of tissue specimens Alternate body fluid specimens (e.g. CSF, breast milk, etc.) Dried specimens as matrices Automation of sample processing Topics will be covered through lecture, Q&A, Case Studies, and small group exercises. 1898

Friday 1400 1800

Short Course: Data Science 201 : Going Further With R: Tackling Clinical Laboratory Data Manipulation and Modeling @ Colton Patrick Mathias, MD, PhD University of Washington Patrick Mathias, M.D., Ph.D., is a board-certified clinical pathologist and Associate Director of Informatics for UW Laboratory Medicine. Lab medicine has large impact on the general practice of medicine. It is key to correctly diagnosing diseases and selecting the right treatments for patients. Dr. Mathias's goal is to combine technical and medical knowledge to fulfill the triple aim--reduce the per capita cost of health care, improve the health of populations and most importantly improve the patient experience of care. Dr. Mathias earned his M.D. and Ph.D. from the University of Illinois. His clinical and research interests include clinical informatics, clinical chemistry and molecular diagnostics. Financial Disclosures (past 24 months as of Feb 13, 2024) : none Shannon Haymond, PhD Northwestern University Feinberg School of Medicine My lab performs research and clinical testing using mass spectrometry methods, develops new assays, and applies data analytics to enable improved quality and efficiency. My computational pathology efforts are aimed at building the capacity for advanced data analytics in the department through innovations in infrastructure, education, and research to facilitate data-informed decision making for clinical care, operations, and quality assurance. Financial Disclosures (past 24 months as of Feb 13, 2024) : none ** Part In-Person and Part Online ** This is the first segment (4 hr) of a 16 hour, part in-person and part online, short course. Segments 2, 3 and 4 will take place ONLINE on April 28,29 and 30, 2022 While attending this IN-PERSON segment is FREE, the ONLINE attendance is fee-based. You can REGISTER HERE. ---------- Having completed your first steps into the wonderful world of data analysis with R (Data Science 101 with Daniel Holmes), would you like to go further? You’ve learned the basics of R, so now it’s time to put that knowledge to work and tackle some interesting clinical applications. Along the way you will also be introduced to even more of capabilities of R and the tools developed by the amazing R community. The course will be run over two days and time will be split between lecture sessions, individual problem solving, and a highly interactive group-level data mining of real data sets (there may even be prizes). Like the introductory course, this class will maintain the “no student left behind policy”. Students will be given time to solve problems taken from real life laboratory work and to do some more advanced analysis on large scale data sets. All attendees will need to bring a laptop with the R language installed and R Studio interface installed. Students may use Windows, Mac OSX or Linux environments. Both R and R studio are free (as in “Free Beer”) and open-source. Students should be prepared continue to expand their skill in programming – which, as you learned in the introductory course can be a little frustrating, but not as frustrating as not being able to get the computer to do what you want at all! Obtaining the Software !!! DOWNLOAD PROGRAM PACKAGES PRIOR TO ARRIVAL ONSITE !!! THERE WILL NOT BE OPEN INTERNET WIFI IN THE CONFERENCE CENTER. !!! POWER : Make sure your computer is charged to hold power for 4 hrs, as power outlets may not be available. Instructions for installing the R language are here: http://cran.r-project.org/ Instructions for installing R Studio are here: http://www.rstudio.com/ Course Description The course will cover: Core concepts in reproducible data analysis Introduction to version control Using R Markdown for reproducible reports Advanced file reading capabilities Scaling up your data transformation skills Cleaning dirty data and managing timestamps Joining data sets together Connecting R to databases Prediction with linear regression and classification with logistic regression 1903

Friday 1800 2000

Closing Dinner Reception @ Jacks Jacks Club Room 1887

Friday 2000

After Hours Activity Suggestions @ Off-site *These are non-MSACL-sponsored activities. Alvarado Brewery. Club Cibo - $5 drinks all night. 1893